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Chapter 1
Aim and Outline of the Thesis
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AIM AND OUTLINE OF THE THESIS
Intestinal inflammation is almost invariably accompanied by intestinal dysfunction
which constitutes a major clinical complication. Current therapy is often inadequate
due to incomplete knowledge about the mechanisms causing intestinal dysfunction
in intestinal inflammation. Nitric oxide (NO) may be a key component in this process.
NO is a highly reactive compound that is produced by three isoforms of Nitric
Oxide Synthase (nNOS, eNOS and iNOS). The two constitutively expressed isoforms,
nNOS and eNOS, are important for peristalsis and maintaining mucosal blood flow,
respectively. The inducible isoform, iNOS, produces large amounts of NO for a limited
period of time and is an element of the innate immunity. Excessive and prolonged
NO production has been suggested to cause intestinal dysfunction in inflammatory
bowel disease (IBD) and sepsis. However, considering the physiological role of NO,
inhibition of NO generation could have deleterious effects. The aim of this thesis
was to determine the expression, regulation and function of iNOS in intestinal
inflammation. In this thesis we asked ourselves if and how NO contributes to
inflammation and dysfunction of the intestine in patients with IBD and whether
inhibition of iNOS could be a treatment option for these patients.
INOS EXPRESSION
In chapters 2 and 3, we studied the expression of iNOS in intestinal biopsies and
circulating monocytes of patients with IBD. In chapter 2 we describe that iNOS is
predominantly expressed in intestinal epithelial cells of the inflamed mucosa and in
chapter 3 that circulating monocytes of patients with active IBD express small
amounts of iNOS. In chapters 4 and 6, we investigated the expression of iNOS in
experimental models of intestinal inflammation. In an experimental animal model of
IBD (CD45RBhigh T cell transfer in SCID mice),epithelial iNOS expression was
demonstrated to be an early event in the development of colitis (chapter 6). In an
experimental animal model of sepsis (LPS injection in rats), high expression of iNOS
was observed in the epithelial cells of the small intestine and to a lesser extent in
the epithelial cells of the colon (chapter 4).
INOS REGULATION
In chapters 4 and 5, we studied the regulation of iNOS in experimental animal
models of colitis and sepsis, and in a human intestinal cell line. Since inflammation is
always associated with oxidative stress, we also studied the regulation of iNOS and
heme oxygenase-1 (HO-1) during oxidative stress. HO-1 is an important enzyme
that produces CO, which may attenuate the inflammatory response during oxidative
11
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stress. In chapter 4 we report that the induction of iNOS in intestinal epithelial
cells is regulated by the transcription factor κB (NF-κB). Furthermore, we
demonstrate an opposite regulation of iNOS and HO-1 in intestinal epithelial cells
in response to cytokine exposure and the oxidative stress-inducing agents diethyl-
maleate (a thiol-modifying agent) and 4-hydroxynonenal (a lipid peroxidation end
product). Interestingly, the induction of iNOS in epithelial cells was dependent on T-
helper cells and bacterial flora, implying a crucial role of these cells in controlling
NO-production by intestinal epithelial cells (chapter 5).
INOS FUNCTION
In chapter 3, 6 and 7 we studied the function of iNOS and its product NO in
intestinal inflammation. In chapter 3, we report that iNOS is expressed in circulating
monocytes of patients with active IBD. However, we did not observe any significant
monocyte activation. In fact, the HLA-DR expression is reduced in patients with
ulcerative colitis suggesting a suppressing effect of NO on monocyte activation. In
chapter 6 we studied the contribution of different NOS isoforms during experimental
TNBS-induced colitis in eNOS, nNOS or iNOS-knockout mice, respectively. Both
eNOS and iNOS knockout mice developed a more severe colitis than wildtype
mice. These results suggest a protective role for both iNOS and eNOS during colitis.
In the final chapter (chapter 7) we discuss that selective inhibition of NF-κB in
inflammatory cells of the intestine may be a possible treatment of IBD. However,
there is concern about the consequence of blockade of NF-κB-mediated survival
pathways in intestinal epithelial cells.
C H A P T E R  1
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Chapter 2
Targeting Nitric Oxide in the Gastrointestinal Tract
Gerard Dijkstra, Harry van Goor1,
Peter L.M. Jansen and Han Moshage
Department of Gastroenterology and Hepatology,
and Department of Pathology1,
University Hospital Groningen, The Netherlands
Current Opinion in Investigational Drugs (in press)
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INTRODUCTION
The overall function of the gastrointestinal (GI) tract is to take up nutrients and
remove waste. The major physiologic processes that occur in the GI tract are motility,
secretion, digestion, absorption and elimination. Nitric oxide (NO) plays a critical
role in several of these physiological processes (figure 1). In this review some impor-
tant aspects of nitric oxide (NO) in the pathophysiology of diseases of the GI tract
(table 1) are discussed.
Figure 1. Diagram of the effects of NO in the gastrointestinal tract.
SOURCES OF NITRIC OXIDE IN THE GASTROINTESTINAL TRACT
In the human gut there is enzymatic, non-enzymatic and bacterial production of
NO. Two constitutively expressed calcium dependent isoforms of nitric oxide synthase
(NOS) are responsible for the enzymatic production of small amounts (nanomolar)
of NO: neuronal NOS (nNOS, type I), and endothelial NOS (eNOS, type III). These
isoforms are primarily regulated by intracellular calcium, via Ca2+activated calmodulin.
The third, inducible isoform (iNOS, type II) is not regulated by calcium because
15
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activated calmodulin is inserted at the time of synthesis. This isoform produces
large amounts of NO (micromolar) for a limited period of time (figure 2). The
induction of iNOS usually occurs in states of inflammation and immune activation.
In the gut, inflammatory 1, epithelial 1, endothelial 2 and neuronal cells 3 can express
iNOS 4. There are several NOS -independent mechanisms of NO formation. For
example, xanthine oxidoreductase is an enzyme that under hypoxic conditions can
produce NO by reduction of nitrate (NO3-) and nitrite (NO2-). NO can also be
formed from dietary nitrate which in the oral cavity is reduced by bacterial reductases
to nitrite 5. This nitrite can be acidified in the gastric lumen yielding NO gas 6,7. NO
Table 1. Involvement of nitric oxide (NO) in the pathophysiology of diseases of the GI tract.
Action Main function Involved Diseases
non-adrenergic non-cholinergic peristalsis, relaxation of oesophageal spasms,




smooth muscle relaxant sphincter relaxation gastro-oesophageal reflux
disease,  achalasia, infantile
hypertrophic pyloric stenosis,
sphincter of Oddi dysfunction,
Hirschsprung’s disease, healing
of anal fissura
maintaining mucosal blood flow gastro-intestinal  ulcers
inhibition of platelet aggregation mucosal protection against NSAID gastropathy, celiac
and leukocyte adhesion, mast cell injury and inflammation disease,inflammatory bowel
stabilisation, increasing mucus disease, diverticulitis
production, inhibition of Th1
cytokine production
oxygen radical; reaction with bactericidal infectious diarrhoea, Helicobacter
superoxide, iron and thiol groups pylori infection, increased
permeability in sepsis,
induction or inhibition of actions of laxatives, bile acid
chloride secretion induced diarrhoea, microscopic
colitis
induction or inhibition of intestinal metaplasia, colonic
apoptosis polyp and tumour development.
carcinogen (nitrosamines) carcinogenesis in the GI tract
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production from the reaction of hydrogen peroxide with arginine is another example
of non-enzymatic NO production 8. Finally anaerobic bacteria in the colon produce
NO, using nitrite and nitrate as substrates 9,10.
NITRIC OXIDE IN INTESTINAL MOTILITY
Motility of the GI tract is directly controlled by enteric inhibitory and excitatory
motor neurons that innervate the smooth muscle layers. Distension of the gut occurs
by a food bolus. This distension is detected by local enteric afferent neurons. These
neurons project to interneurons, which send their stimulus either upstream (orally)
or downstream (aborally). Upstream interneurons are stimulatory and induce
contractions via the neurotransmittors acetylcholine and substance P. Downstream
interneurons are inhibitory and act via the neurotransmittors somatostatin, γ-
aminobutyric acid (GABA). These inhibitory interneurons regulate other interneurons
that use endogenous opiates, vasoactive intestinal peptide (VIP) and NO to inhibit
muscular contraction. About 50 % of the nerves in the enteric nervous system
contains nNOS. These nerves are located in the myenteric plexus and muscle fibers.
Bult and colleagues were the first to demonstrate that NO is the most important
non-adrenergic, non-cholinergic (NANC) inhibitory neurotransmitter in the gut 11.
Inhibitory motor neurons mediate receptive and accommodative relaxations and
control the opening of sphincters. Indeed nNOS-/- mice showed increased lower
oesophageal sphincter (LES) relaxations and gastroparesis 12. Impaired NO release
is observed in diseases with non-relaxing sphincters or bowel segments like achalasia 13,











Figure 2. Nitric Oxide Synthase catalyses the synthesis of nitric oxide from L-arginine an molecular
oxygen. L-citrulline is the byproduct. NADPH, BH4 FAD,FMN and CaM act as co-factors.
17
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therapy may perhaps in the future become a new treatment options. Topical NO
donors have already been used in patients undergoing endoscopic retrograde
cholangiopancreaticography (ERCP) to relax the sphincter of Oddi and inhibit
duodenal motility 16. Isosorbide dinitrate (ISDN) ointment is locally applied to relax
the anal sphincter in order to heal anal fissures 17. Furthermore, ISDN tablets are
used to treat oesophageal spasms 18. Transient LES relaxation (TLESR) are impor-
tant in gastroesophageal reflux disease (GERD). Intravenous infusion of the NOS
inhibitor N-monomethyl-Arginine (L-NMMA) in healthy volunteers caused a decrease
in the gastric distension-triggered TLESR’s and an increase in oesophageal peristaltic
amplitude and velocity. This indicates that inhibition of NO might be of benefit for
patients with GERD 19.
The contractile activity of the gut has an intriguing pattern, which is known as
the migrating motor complex (MMC). This MMC has three phases of activity with
minimal contractile activity in the fast state (phase I), mixing contractility in the fed
state (phase II) and high amplitude peristaltic contractions (phase III). Several stu-
dies have shown that inhibitors of NOS initiate premature phase III contractions
whereas NO donors disrupt the MMC 20-22. Therefore, selective inhibition of nitric
oxide synthase could be a treatment option in patients with bacterial overgrowth
due to an impaired phase III activity. Also a toxic megacolon in patients with ulcerative
colitis is propably to a certain extent caused by overproduction of NO by highly
induced iNOS in the colonic smooth muscles. Selective iNOS inhibition could be a
treatment strategy in this life threatening condition 23. Several motility disorders like
chronic intestinal pseudo-obstruction and even constipation might relate to the
enteric NO system, thereby suggesting new pharmacological treatment options.
NITRIC OXIDE IN INTESTINAL SECRETION AND ABSORPTION
In the gut lumen, NO has a half life of less than 6 seconds, and is rapidly converted
into nitrite and nitrate in the presence of oxygen and water. It is highly diffusible in
water, lipids, and air and it freely traverses cell membranes and passes into adjacent
target cells. NO is involved in the intestinal water transport by acting directly on
the epithelium and bloodflow or indirectly by stimulating neuronal reflexes, and
releases of, or interactions, with other agents. For example, NO activates soluble
guanylate cyclase and this results in cGMP generation, a potent activator of intestinal
secretion 24. NO can also induce vasoactive intestinal polypeptide (VIP) an impor-
tant neurotransmittor in secretomotor neurons 25. Furthermore, NO causes an
increase of prostaglandin (PG) E2 production, a known secretory molecule 26. Apart
from indirect effects on secretory molecules, NO may also exert direct secretory
effects by opening of chloride channels 27. NO is one of the mediators of the intestinal
secretion and laxative induced diarrhoea induced by castor oil 28, magnesium sulfate 29,
and anthraquinone containing laxatives such as senna and cascara 30, as well as the
C H A P T E R  2
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diphenylmethanes: phenolphthalein and bisacodyl 31. Bile acid infusion in the left
colon induces NO generation suggesting that NO is also involved in bile salt induced
diarrhoea 32. Patients with collagenous or lymfocytic colitis produce watery diarrhoea
in the absence of epithelial cell damage. High levels of NO gas in the gut lumen of
these patients suggest a role of NO in inflammation induced diarrhoea 33. Topical
administration of the NOS inhibitor Ng-monomethyl-L-arginine (L-NMMA) reduced
fluid secretion in patients with collagenous colitis 34. In contrast NO can also reduce
fluid secretion as demonstrated in Clostridium difficile 35 and cholera toxin 36 induced
diarrhoea. Early studies with NOS inhibitors already showed that NO promotes
absorption under basal conditions (for review see 37). Interestingly the secretory
effect of the NOS inhibitor NG-nitro-L-arginine (L-NAME) could be reversed by
loperamide a known antidiarrhoeal opiod. The mechanisms of the proabsorptive
actions of NO are not fully understood but may involve the opening of basolaterally
located potassium channels in enterocytes 38. In summary it seems that NO can act
both as a secretagogue and an absorbagogue depending on the concentrations, local
circumstances and on the site of delivery.
NITRIC OXIDE IN INTESTINAL INJURY, REPAIR, CARCINOGENESIS AND
APOPTOSIS
The GI tract is remarkably protected against damage by ingested irritants (food
components, alcohol, drugs); endogenous secretions (acid, bile, proteolytic enzymes)
and potentially harmful actions of enteric microbes. The mucosal barrier is composed
of a rapidly replaced monolayer of intestinal epithelial cells (IEC) and non-specific
agents such as lysozyme, acid and mucus. NO is important in maintaining mucosal
integrity by several mechanisms. A continuous supply of blood to the gastrointestinal
mucosa is vital during periods of injury. Especially eNOS derived NO plays an impor-
tant role in the calcitonin gene-related peptide (CGRP) mediated, reactive hyperaemic
response to mucosal injury 39. Studies with irritants like ethanol 40,41, hydrochloric
acid 42 or the vasoconstrictive agent endothelin 43 showed reduced gastric mucosal
damage when NO donors were administered while gastric mucosal damage was
increased when NO scavengers or NOS inhibitors were given.These findings spurred
the development of adding NO donating groups (nitroxybutyl) to known ulcerogenic
non steroidal anti-inflammatory drugs (NSAIDs). Indeed, NO-NSAIDs did not cause
the gastric mucosal injury normally associated with NSAIDs 44 and could even protect
against gastric mucosal injury associated with endotoxin 45 or hemorrhagic 46 shock.
Apart from increasing mucosal blood flow 47, the protective actions of NO may also
involve reduction of leucocyte adherence 48, inhibition of mast cell activation 49,
inhibition of Th1 type cytokines by inactivation of cytokine processing 50, and
stimulation of gastric mucus secretion 51. In addition to its protective actions in
response to injury, NO is also a modulator of mucosal repair. Konturek et al
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demonstrated retarded gastric ulcer healing by NOS inhibitors and accelerated healing
by the NO donor glyceryl trinitrate 52. Delayed ulcer healing was also found in iNOS
knockout mice with acetic-acid induced colitis 53. Studies with cutaneous wounds
demonstrated that NO enhances collagen production by fibroblasts 54.Transfection
with the gene for iNOS into the wound of the skin had beneficial effects 55.
Angiogenesis is important in both wound repair and carcinogenesis. NO derived
from eNOS expressed in mammary tumor cells promoted tumor growth and
metastasis by stimulation of tumor cell migration, invasiveness and angiogenesis 56.
However, in another study with colon carcinoma cells the presence of eNOS inversely
correlated with their metastatic potential 57. In this study the absence of NO
production in metastatic cells induced platelets aggregation that increased the
adhesion of metastatic cells to the vascular endothelium and promoted their
successful implantation. Precancerous lesions such as gastric intestinal metaplasia 58
and colonic polyps 59 express iNOS. Selective inhibition of iNOS showed a reduced
development of aberrant crypt foci indicating that specific iNOS inhibition could be
a chemopreventive strategy for colon cancer 60. Early studies concerning the role of
NO in carcinogenesis were focused on its potential to nitrosate (addition of NO+)
amines, including those in DNA, forming nitrosamines. Nitrosamines can lead to
direct mutations or to the generation of carcinogens 61. NO may also potentiate
DNA damage by inhibition of DNA repair mechanisms 62.
The capacity of NO to induce apoptosis was first appreciated by Albina 63, who
showed that NO caused apoptosis in macrophages. Accumulation of the tumor
suppressor protein p53 has been described as an essential and early indicator of
NO-induced apoptosis 64. Although high concentration of NO is a well-established
cytotoxic and pro-apoptotic effector molecule, there is growing evidence that low
concentrations of NO can also inhibit apoptosis. First, NO can oxidize intracellular
reduced glutathione and thereby change the antioxidant levels within the cell, resulting
in oxidative or nitrosative stress. This stimulates the induction of heat shock proteins
HSP32 and 70, which protects cells from apopoptic cell death 65. Second, caspase
proteases contain a single cysteine at the catalytic site that is essential for activity.
Suppression of the effector caspase-3 activity by S-nitrosylation of the essential
cysteine cys163 can block apoptosis 66. Finally, NO may inhibit cytochrome C release
from mitochondria by inhibiting bcl-2 cleavage 67. Thus, NO may act as a bifunctional
regulator of apoptosis with inhibition of apoptosis in case of oxidative stress as
present in mucosal injury and induction of apoptosis in carcinogenesis.
NITRIC OXIDE IN INTESTINAL INFECTION AND INFLAMMATION
Despite intestinal barriers there is a constant interaction between antigens in
the gut lumen and the mucosal immune system. The presence of inflammatory cells
in the gut mucosa reflects this “tolerant” mucosal immune response against the
C H A P T E R  2
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normal gut content. NO plays an important role in both barrier and immune function.
Inhibition of NO with NG-nitro-L-arginine (L-NAME) resulted in a rapid increase of
trans-epithelial movement of the small molecule 51 Cr-EDTA (MW 330) 68 indicating
increased permeability. The increased permeability for small molecules occurred
without overt injury and could be restored by exogenous NO suggesting that NO
maintains an intact mucosal barrier. However, intestinal epithelial cells (IEC) exposed
to high amounts of NO showed increased permeability 69. Induction of iNOS can
yield micromolar amounts of NO for sustained periods. The induction of iNOS is
mediated by the nuclear transcription factor κB (NF-κB)70. Various stimuli like viruses,
microbial products, pro-inflammatory cytokines (TNF-.α, IL-1, IL-6), T-and B-cell
mitogens, physical and chemical stress can activate NF-κB 71. Because a combination
of cytokines (IL-1, IFN-γ TNF-α) and endotoxin (LPS) are needed for the in vitro
induction of iNOS in native colon cells and in intestinal tumour cell lines these cells
are believed to be relatively resistant to cytokine induced NF-κB activation. A
decreased IκB kinase (IKK) activity and consequent resistance to IκBα degradation
is postulated as a protective response of IEC’s to remain quiescent in the hostile
colon environment 72. Indeed, many immunohistochemical studies 73,23,74,75 even
combined with Western blotting 1,76could not demonstrate epithelial iNOS expression
in normal gut mucosa. However, Roberts et al.77 found iNOS mRNA and Perner et
al.78 demonstrated iNOS protein expression in the normal colonic mucosa suggesting
a low grade physiological induction of iNOS in the normal colon.
Despite relative resistance of IEC’s to NF-κB activation several pathogenic
organisms such as Salmonella, Shigella, Listeria and Helicobacter species can activate
NF-κB 79 and induce iNOS 80 in IEC’s. NO in itself may not be toxic to bacteria, in
fact certain enteric bacteria contain nitrate reductase and produce NO by their
own. However, NO becomes cytotoxic when generated together with superoxide
(O2•-) forming peroxynitrite (OONO-) a powerful antimicrobial agent 81. Epithelial
iNOS induction has clearly been demonstrated in inflammatory conditions such as;
diverticulitis 1, inflammatory bowel disease (IBD) 1,23,75,76, and celiac disease 82. Epithelial
iNOS induction and NO production may cause increased intestinal permeability as
observed in septic patients 83. Indeed selective inhibition of iNOS in endotoxemic
rats ameliorated mucosal permeability for dextran (MW 4000) 84 and reduced
bacterial translocation 85. The absence of bacterial translocation in endotoxemic
iNOS knockout mice further supports a pathogenic role of epithelial derived NO in
sepsis.
The role of NO in IBD is less obvious. NO can react with superoxide (O2•-)
anions yielding the toxic reactive nitrogen intermediate peroxynitrite (OONO-)86.
In addition to oxidation reactions, peroxynitrite can nitrate tyrosine to produce 3-
nitrotyrosine. Evidence for peroxynitrite mediated damage of epithelial cells in IBD
was found in one 1 but not in two other studies 75,76. Studies using inhibitors of NOS
in experimental colitis showed little improvement 87,88; no effects 89,90, or even worse
effects 91 on colitis probably due to the lack of iNOS specificity of the inhibitors
21
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used. The first report of experimental colitis in iNOS knockout mice showed delayed
healing and persistent inflammation in acetic-acid induced colitis 53. Studies with
trinitrobenzene sulphonic acid (TNBS) induced colitis in iNOS KO mice showed
resistance to TNBS colitis in one 92 and increased inflammation in two other studies
93,94. In the dextran sulphate sodium (DSS) colitis model in iNOS KO mice showed
resistance to DSS in three studies 95,96,97. Finally, a chronic colitis which develops
spontaneously in interleukin 10 (IL-10) deficient mice, developed at the same rate
and intensity in mice deficient in both the IL-10 and iNOS genes 98. Considering the
absence of macroscopic ulcerations in the presence of large amounts of NO in
patients suffering from microscopic colitis a protective role of NO is suggested 99.
Indeed a NO donating mesalazine derivative had an additional beneficial effect on
TNBS induced colitis 100. The reduced gastro-intestinal toxicity of NO donating non
steroidal anti-inflammatory drugs (NSAID) 44 and aspirin 101 are in agreement with a
protective effect of NO on intestinal epithelial cells. Apart from the above-mentioned
beneficial effects of NO in mucosal injury, NO can also inhibit NF-κB activation 102.
Therefore high amounts of NO may serve in a negative feedback loop to block
prolonged activation of NF-κB thereby limiting chronic inflammation.
CONCLUSIONS
It is clear that nanomolar amounts of NO produced by calcium dependent nNOS
has a physiological role in peristalsis and sphincter function. Absence of locally
produced NO can result in aperistalsis and obstructive sphincters. NO produced by
eNOS is essential in maintaining mucosal blood flow. Abscence of NO results in an
increased susceptibility of the GI tract to injury.
Selective NO delivery by gene therapy or by NO donating compounds might
offer new therapeutic options in motility disorders of the gut or to prevent mucosal
injury. The effects of micromolar amounts of NO as produced by iNOS are less well
understood. On the one hand large amounts of NO can increase gut permeability,
induce apoptosis and stimulate intestinal secretion. On the other hand NO can
block apoptosis and reduce inflammation by inhibiting NF-κB activation. Further
studies with selective iNOS inhibition by specific iNOS blockers or anti-sense therapy
are needed to elucidate the role of NO in the gastrointestinal tract.
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ABSTRACT
Nitric oxide (NO) and reactive oxygen species (ROS) are important mediators
in the pathogenesis of inflammatory bowel disease (IBD). NO in IBD can either be
harmful or protective. NO can react with superoxide anions (O2•-) yielding the
toxic oxidizing agent peroxynitrite (ONOO-). Peroxynitrite induces nitration of
tyrosine residues (nitrotyrosine) leading to changes of protein structure and function.
The aim of this study was to identify the cellular source of inducible nitric oxide
synthase (iNOS), and to localise superoxide anion producing cells in mucosal biopsies
from patients with active IBD. Additional studies were performed to look at
nitrotyrosine formation as a measure of peroxynitrite mediated tissue damage. For
this antibodies against iNOS, eNOS, and nitrotyrosine were used. ROS producing
cells were detected cytochemically. Inflamed mucosa of patients with active IBD
showed intense iNOS staining in the epithelial cells. iNOS could not be detected in
non-inflamed mucosa of IBD patients and control subjects. eNOS was present in
blood vessels, without any difference in staining intensity between IBD patients and
control subjects. ROS producing cells were increased in the lamina propria of IBD
patients, a fraction of these cells were CD 15 positive. Nitrotyrosine formation was
found on ROS positive cells. These results show that iNOS is induced in epithelial
cells from patients with active ulcerative colitis or Crohn’s disease. Nitration of
proteins was only detected in the ROS producing cells at some distance from the
iNOS producing epithelial cells. These findings indicate that tissue damage during
active inflammation in IBD patients is probably more related to ROS producing cells
than to NO. One may speculate that NO has a protective role when during active
inflammation other mucosal defence systems are impaired.
INTRODUCTION
Inflammatory bowel disease (IBD) is characterised by chronic intestinal in-
flammation. The cellular components of this inflammation are capable to produce
reactive oxygen species (ROS), hydrogen peroxide (H2O2), superoxide anions (O2•-),
and nitric oxide (NO) 1. NO is synthesised from L-arginine by the enzyme nitric
oxide synthase (NOS). The constitutive (calcium dependent) isoforms, neuronal NOS
(nNOS or bNOS) and endothelial NOS (eNOS), produce small amounts of NO
which acts as a neurotransmittor and vasodilator respectively 2. The inducible (calcium
independent) isoform (iNOS) produces much larger amounts of NO and is only
expressed during inflammation. iNOS is induced by cytokines like interferon-gamma
(IFN-γ), tumor necrosis factor α (TNF-α), interleukin-1 (IL-1) and lipopoly-
saccharide (LPS). iNOS induction is suppressed by transforming growth factor β
(TGF-β), and interleukin -8 and -10 (IL-8,-10) 3. These inducer and suppressor
cytokines are important in the inflammatory response as present in IBD. Cytokines
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that induce iNOS mediate their effects to a large extent via the transcription factor
NF-κB 4. Steroids inhibit the induction of iNOS 5 and NF-κB 6.
NO can be directly cytotoxic but can also react with superoxide anions (O2•-)
yielding the oxidizing agent peroxynitrite (ONOO-). Peroxynitrite can cause tissue
damage by lipid peroxidation, oxidation of sulfhydryl groups of proteins, and nitration
of aromatic amino acids like tyrosine, yielding nitrotyrosine 7. Nitration of tyrosine
residues may lead to loss of protein structure and function.
Many manifestations of IBD, including mucosal vasodilatation, enhanced vascular
and epithelial permeability and disturbed motility, are consistent with direct or indirect
biological effects of NO. There is growing evidence that NO production is enhanced
in IBD. End metabolites of the L-arginine-NO pathway like citrulline and nitrite
were increased in blood 8, urine 9, and rectal dialysates10 of ulcerative colitis (UC)
patients with active inflammation. In UC patients NO could also be detected directly
in gas from the colon lumen 11. Although early studies only found an increased
mucosal NOS activity in UC 12 later studies also showed an increased mucosal NO
production in Crohn’s disease (CD) 13,14.
The source and function of the enhanced NO production in IBD is unclear.
Considering the beneficial effect of iNOS inhibitors (steroids, anti-TNF-α 15, IL-10 16,
anti-sense NF-κB 17) in IBD one could postulate that NO is harmful. However,
animal studies using NOS inhibitors 18,19 and iNOS knock out mice 20 showed an
aggravation of inflammation. The aim of the present study was to identify the cellular
source and distribution of the iNOS and eNOS isoforms in mucosal biopsies obtained
from patients with active IBD. Considering the possible interaction between NO
and superoxide anions we also investigated the distribution of superoxide anion
producing cells and nitrotyrosine.
MATERIALS AND METHODS
Subjects
Biopsy specimens were obtained from patients undergoing colonoscopy or
sigmoidoscopy. Clinical information about the diagnosis, medication, current clinical
status, colonoscopic findings, and results of radiological and laboratory investigations
were collected using a standard protocol.
Ulcerative colitis (UC) patients comprised 6 men and 4 women; mean age 37
years (range 21-57). Two patients did not have previously documented UC, one of
them used aspirin. The remaining 8 patients were known with UC and were referred
because of disease activity. Medication consisted of mesalazine in two, prednisolone
in one and mesalazine combined with prednisolone in 5 patients. On colonoscopy
there were 7 patients with disease extending above the sigmoid colon (extensive
UC) and 3 patients with procto-sigmoiditis only (distal UC).
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Crohn’s disease (CD) patients comprised 4 men and 6 women; mean age 30
(range 18-49). Three patients were not previously known with CD, one used inhalation
steroids and loratidin for asthma and another patient used vigabatrine for epilepsy.
Medication of the remaining 7 patients known with CD consisted of prednisolone
in one, mesalazine in one, and the combination of prednisolone and mesalazine in
five patients. Of these five patients two also used azathioprine, and one patient also
used methotrexate. All patients had colitis and one patient also had a terminal ileitis.
Control subjects comprised 4 men and 3 women; mean age 41 (range 33-61)
with an irritable bowel syndrome (4), diverticulosis (2) and a solitary rectal ulcer
(1). Biopsies were taken from macroscopically normal mucosa and all had normal
levels of C-reactive protein.
Specimen collection
Biopsies were taken using a standard biopsy forceps during videoendoscopy and
were obtained from the rim of ulceration’s or aphtoid lesions if present. Biopsies
were also obtained from macroscopic inflamed mucosa. In 2 patients with UC, and
4 patients with CD we also obtained biopsies from macroscopic non-inflamed mucosa.
The biopsies were collected in Hank’s balanced salt solution, frozen in isopentane
and stored at –80 °C.
Nitric Oxide Synthase detection
Cryosections (4 µm) were fixed in 4% paraformaldehyde for 5 minutes. For
iNOS detection, an affinity-purified polyclonal rabbit IgG against the C-terminus
amino acids 1135-1153 of human iNOS (cat # SC-649, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and a mouse IgG1 monoclonal antibody against amino acids
961-1144 of the C-terminus of mouse iNOS (cat # N39120, Transduction Labora-
tories, Lexington, KY, USA) were used. For eNOS detection a mouse monoclonal
antibody against amino acids 1030-1209 of human eNOS (cat # N30020, Transduction
Laboratories, Lexington, KY, USA) was used. Endogenous peroxidase was blocked by
treatment with 0.075 % H2O2 in phospate buffered saline (PBS) for 30 minutes.
Peroxidase conjugated rabbit antimouse IgG and goat anti rabbit IgG were used as
secondary antibodies. The peroxidase activity was developed with 0.2 mg/ml 3-amino-
9-ethyl-carbazole (AEC) in sodium acetate buffer containing 0.03 % H2O2, for 10
min. Slides were counterstained with haematoxylin and coated with glycerin/gelatin.
Nitrotyrosine detection
Cryosections (4 µm) were fixed in acetone for 10 minutes and incubated with
an affinity purified rabbit polyclonal antibody (cat # 06-284, Upstate Biotechnology,
Lake Placid, NY, USA) against nitrotyrosine 21. Endogenous peroxidase was blocked
by treatment with 0.075 % H2O2 in PBS for 30 minutes. Peroxidase conjugated goat
anti-rabbit IgG was used as a secondary antibody. The peroxidase activity was
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developed with AEC. Slides were counterstained with haematoxylin and coated with
glycerin/gelatin.
Immunohistochemistry controls
Specificity of staining with antibodies against iNOS, eNOS, and nitrotyrosine
was confirmed by 1) performing the immunohistochemical staining with omission of
the primary antibodies 2) pre-incubation of the anti-iNOS (Santa Cruz) antibody
with the peptide used as immunogen (cat # SC-649 P) and of the nitrotyrosine
antibody with 3-nitrotyrosine. The eNOS and iNOS protein fragments used to raise
the Transduction Laboratories antibodies against eNOS and iNOS were not available
for inhibition studies. Finally, all antibodies were tested on Western-blot using lysates
of stimulated mouse macrophages and human endothelial cells as positive controls
for iNOS and eNOS respectively.
Reactive oxygen species detection
A cytochemical technique specific for superoxide anion production by leucocytes
was used 22. Briefly, cryosections (4 µm) were incubated in a buffer containing 1 mM
azide to inhibit endogenous peroxidase activity, diaminobenzidine (DAB) and Mn++.
Superoxide (or a derivative) oxidises Mn++ to Mn+++, the latter having the ability to
oxidise DAB, resulting in the deposition of an electron dense reaction product. The
slides were counterstained with hematoxylin and coated. The number of ROS positive
cells was analysed blinded using an Olympus BX50 microscope (Olympus, Japan), a 2
CCD camera (Sony, Japan), and then processed by an image analysis system (Qwin
version 2.0, Leica Imaging Systems).The number of ROS positive cells was counted
per mm2 mucosa. An average of 87, 110, and 117 mm2 mucosa per subject was
quantitated in the control, UC and CD group respectively. The specificity for
superoxide anion detection was checked by performing the staining 1) in absence
of manganese 2) in the presence of catalase (500 U/ml) 3) in the presence of
superoxide dismutase (300 U/ml). Determination of the identity of ROS positive
cells was performed using antibodies against mast cells (AA1, Dako, Glostrup,
Denmark), eosinophils ( Eg2, Sanbio, Uden, the Netherlands), CD 3, CD 8, CD 10,
CD 14, CD 15 (Becton-Dickinson, Bedford MA, USA) and CD 68 (Dako, Glostrup,
Denmark).
Statistics
The ROS positive cells counts had a normal distribution and accordingly a two
tailed Student’s t-test for unpaired data, with Welch’s correction for differences in
variance, was applied to determine differences in cell counts between and within
subject groups. The cell counts are given as the mean ± the standard error of the
mean.
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Figure 1. Serial sections of a mucosal biopsy from a patient with Crohn’s disease (A-E) and a
control subject (F-J). Haematoxylin and eosin staining shows inflamed mucosa (A, arrow at
cryptabces) and mucosa from the control subject (F). Anti-iNOS staining shows intense epithelial
staining in the inflamed mucosa (B) without staining in the mucosa of the control subject (G). Anti-
eNOS staining shows endothelial staining in the inflamed (C) and in the mucosa of the control
subject (H). Staining of reactive oxygen species producing cells showing abundant positive cells in
the lamina propria of the Crohn’s disease patient (D) and sparse positive cells in the control
subject (I, arrow head). Staining with anti-nitrotyrosine shows positive cells in the inflamed
mucosa (E) and the mucosa of the control subject (J).
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RESULTS
Detection of iNOS
Inflamed mucosa of all UC and CD patients showed a strong expression of
iNOS in the epithelial cells (Fig.1.B). The distribution was focally with more intense
staining at the apical sites of the crypts. iNOS expression was located immediately
adjacent to ulcerated areas with intense inflammatory cell infiltration in the lamina
propria. In 1 control subject, 2 patients with UC and 5 patients with CD a few
inflammatory cells in the lamina propria were weakly iNOS positive. Identical staining
patterns were observed with the two iNOS antibodies used. Uninflamed mucosa of
2 UC, and 4 CD patients and the mucosa of the control subjects (Fig.1.G) showed
no iNOS expression. Omission of the primary antibody as well as pre-incubation of
the iNOS antibody from Santa Cruz with the peptide used as immunogen completely
abolished all staining. The antibody from Transduction laboratories recognised a single
band of approximately 130 KD in a mouse macrophage lysate on Western blot. The
antibody from Santa Cruz did not detect the mouse iNOS in the mouse macrophage
lysate. This is probably due to the low homology between human and mouse iNOS
at the C-terminal region.
Detection of eNOS
eNOS was only present in the endothelium of blood vessels. Immuno-histo-
chemically there was no difference in staining intensity between UC and CD patients
or control subjects (Fig.1.C and H). No staining was detectable when the eNOS
primary antibody was omitted. The antibody recognised a single band of approximately
140 KD in a human endothelial cell lysate on Western blot.
Reactive oxygen species and nitrotyrosine detection
There was a significant increase (Fig.2.) of ROS producing cells in the inflamed
mucosa of UC and CD patients (Fig.1.D) compared to controls (Fig.1.I). The cell
counts for the control, UC and CD group were 2.2±0.7, 7.8±1.9, 14.0±3.0 per mm2
mucosa respectively. There was no difference (p= 0.89) in the number of ROS
producing cells between IBD patients with (10.7±2.8) or without (11.2±2.4)
prednisolone.
ROS-staining was reduced by catalase (90 % reduction) and not by SOD indicating
that in human gut mucosa this staining technique is not specific for superoxide anion
producing cells. Most of the ROS positive cells in IBD patients and control subjects
were also positive for nitrotyrosine (Fig.1.E and J). Nitrotyrosine modified proteins
were found on the surface of ROS-positive cells. Double staining demonstrated
that the ROS-positive cells were negative for Eg2 (eosinophils), AA1 (mast cells),
CD 3, CD 8, CD 10, CD 14 and CD 68. A fraction of the ROS-positive cells were
CD 15 positive, suggestive for monocytes/granulocytes. Most of the ROS-positive
cells were iNOS negative with both iNOS antibodies. Nitrotyrosine could not be
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detected on the epithelium. The nitrotyrosine staining of the ROS-positive cells in
the lamina propria could be completely blocked by pre-incubation of the nitrotyrosine
antibody with 3-nitrotyrosine. In addition, no staining was detectable when the primary
antibody was omitted.
DISCUSSION
In this study intense iNOS staining was found in the epithelium of inflamed
mucosa of both UC and CD patients. This enzyme was expressed focally and could
not be detected in non-inflamed mucosa of IBD patients or control subjects. The
expression of iNOS in the inflammatory cells of the lamina propria was weak and
present in a minority of patients. The immunohistochemical expression of eNOS
does not differ between IBD patients and control subjects. These findings demonstrate
that during inflammation iNOS is pre-dominantly induced in colonic epithelium and
to a much lesser extent in inflammatory cells of the lamina propria. Epithelial
expression of iNOS is not specific for IBD since it was also found in diverticulitis 23.
Singer et al 23 observed nitrotyrosine formation in the inflamed colonic epithelium.
We could not visualise nitrotyrosine-modified proteins in the epithelial layer of the
mucosa. Nitrotyrosine was found at the surface of the ROS-positive inflammatory
cells in the lamina propria at some distance from the iNOS positive epithelium.
Therefore an interaction between superoxide anions produced in the lamina propria
and epithelial derived NO is not likely. In a TNBS induced colitis model in rats distinct
and separate sites of NO production and nitrotyrosine formation was also observed 24.
Despite the use of two different antibodies we could not detect iNOS in the majority
of the nitrotyrosine/ROS-positive cells. In agreement with the findings of Singer et
Figure 2. The number of reactive oxygen species (ROS) producing cells/mm2  mucosa in  patients
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al 23 these nitrotyrosine-positive/iNOS-negative cells were also present in non-
inflamed mucosa of UC patients, CD patients and in control subjects. Since
nitrotyrosine is a relatively stable end-product of peroxynitrite action, nitration
could have occurred earlier. Alternatively, the expression levels of iNOS in the
nitrotyrosine/ROS-positive inflammatory cells could be below the limit of detection.
We found an increased number of ROS-positive cells in the lamina propria of
IBD patients. A small fraction of the ROS-positive cells were CD15 positive suggestive
for monocytes/granulocytes. Activation of peripheral and intestinal mononuclear
cells plays an important role in the pathogenesis of IBD 25. These mononuclear cells
produce ROS that can activate the transcription factor NF-κB 4. NF-κB in turn
induces the expression of pro-inflammatory cytokines and iNOS 26. McLaughlan 27
however, observed high levels of iNOS-mRNA in both UC and CD patients but
could not correlate this with histological demonstration of polymorphonuclear
neutrophil (PMN) infiltration.
The function of iNOS-derived epithelial NO is unclear. It could be protective in
forming an oxidative barrier to bacterial invasion at the site of mucosal injury 28. This
theory is supported by the finding of an increased damage in acetic acid treated
iNOS knock out mice 20. Also the NOS inhibitor Ng-nitro-L-arginine (L-NNA)
aggravated the course of colitis in acetic acid induced colitis in rats 18. However, a
beneficial effect of NOS inhibition was seen in trinitrobenzene sulfonic acid (TNBS)
and acetic acid induced colitis in rats using Ng-nitro-L-arginine methyl ester (L-
NAME) as NOS inhibitor 29. The beneficial effect of L-NAME only occured at a low
dose, a higher dose enhanced mucosal damage in TNBS induced colitis 19. Epithelial
derived NO has been shown to cause diarrhoea 30 or tissue damage 7. However,
diarrhoea in a chronic colitis model in rhesus monkeys did not improve with more
specific iNOS inhibitors like L-N6-(1-iminoethyl) lysine (L-NIL) or aminoguanidine 31.
The different effects of NOS inhibitors could be explained by their specificity for
the different NOS isoforms, the timing of administration, the dosage, and the animal
model used. Altogether the role of NO and NOS inhibitors in human IBD is currently
uncertain and the literature is contradictory.
In our study, we demonstrate that mucosal inflammation is associated with
induction of iNOS in epithelial cells and to a much lesser extent in inflammatory
cells of the lamina propria. The epithelial localisation of iNOS suggests that colonic
epithelium is the major source of the increased NO production observed in IBD.
Considering the absence of peroxynitrite modified proteins in the iNOS positive
epithelial cells and the presence of ROS-positive cells at some distance in the lamina
propria, it seems that peroxynitrite is not involved in NO induced tissue damage.
What could be the role of NO produced by the abundantly expressed iNOS in
mucosal epithelial cells. Is it harmful or protective? Although the data of this study
do not allow solving this intriguing question, one could postulate that NO forms a
direct line of defence against the colonic microflora in a situation wherein the
normal intestinal defence is impaired.
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ABSTRACT
Background: Inducible nitric oxide synthase (iNOS) expression and nitric oxide
(NO) synthesis are increased in epithelial cells and in tissue macrophages of the
inflamed mucosa from patients with inflammatory bowel disease (IBD).
Objective: Since tissue macrophages are derived from circulating monocytes,
we studied iNOS expression in circulating monocytes and we related this expression
with disease activity. In view of the possible role of NO in monocyte function we
also studied iNOS expression in relation to markers of monocyte activation.
Methods: The expression of iNOS in circulating monocytes from 15 patients
with active IBD, 6 patients who went into remission, and 18 healthy controls was
quantified by flowcytometry and correlated with surface markers (CD63, CD11b,
HLA-DR) for monocyte activation. In addition, iNOS expression in circulating
monocytes was assessed by Western blotting, immunocytochemistry, and measure-
ment of the NO metabolites nitrite and nitrate in plasma.
Results: The expression of iNOS in circulating monocytes and the percentage
of iNOS-positive monocytes was increased in patients with active IBD compared to
healthy controls (fluorescence index: 1.3 (0.1-6.3) vs 0.8 (0.0-1.8), p < 0.05; percen-
tage of iNOS positive monocytes: 37.3 (1.0-77.0) % vs 5.3 (0.0-43.3), p < 0.01). The
6 patients who went into remission all had a marked reduction of iNOS expression.
iNOS expression was confirmed by Western blotting and immunocytochemistry.
Plasma nitrite and nitrate levels were elevated in 3 patients with active IBD. The
surface markers for monocyte activation, CD63 and CD11b, were not elevated.
HLA-DR expression was decreased on circulating monocytes from patients with
active ulcerative colitis. Conclusions: iNOS is increased in circulating monocytes
from patients with active IBD and this increased expression correlates with disease
activity. Considering the decreased HLA-DR expression and absence of monocyte
activation markers, NO produced by iNOS, may have a function in suppressing
systemic monocyte activation.
INTRODUCTION
Conflicting data have been reported concerning activation of circulating
monocytes from patients with inflammatory bowel disease (IBD). Increased numbers 1
and increased turn-over 2 of circulating monocytes were found in patients with
active IBD. Evidence for monocyte activation was found in their increased motility,
phagocytosis, spontaneous giant cell formation, superoxide production, and release
of lysosomal enzymes 3,4. In contrast, a deficient spontaneous cell-mediated cyto-
toxicity, antibody-dependent cellular cytotoxicity (ADCC), and hyporesponsiveness
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to activation with interferon-gamma (IFN-γ), and mitogenic lectins have also been
reported 5. Nitric oxide (NO) may be involved in the regulation of monocyte function.
Both NO mediated induction 6 and NO mediated suppression 7 of lipopolysaccharide
(LPS) induced tumour necrosis factor alpha (TNF-α) production by human macro-
phages have been described.
Nitric oxide synthase (NOS) is an enzyme that catalyses the synthesis of NO
and L-citrulline using oxygen and L-arginine as substrates. The enzyme exists in
three isoforms encoded by distinct genes. Two constitutively expressed isoforms,
neuronal NOS (nNOS, type I) and endothelial NOS (eNOS, type III), produce small
amounts of NO (picomolar range) for neuronal and cardiovascular regulatory
processes. The third, calcium- and calmodulin-independent isoform, inducible NOS
(iNOS, type II) is induced by the cytokines TNF-α, interleukin-1 (IL-1), IFN-γ, and by
LPS in a variety of cell types. Physiologic expression of iNOS has been detected in
airway 8 and colonic epithelial cells 9. iNOS produces large amounts (micromolar
range) of NO. Induction of iNOS is suppressed by the interleukins IL-4,-8,-10, -13,
transforming growth factor beta (TGF-β) and by steroids.
In IBD, iNOS is expressed in epithelial cells and in tissue macrophages of the
inflamed mucosa 10-12. iNOS positive tissue macrophages have also been detected in
a-septic bone necrosis 13, breast tumours 14, and tuberculosis 15. Tissue macrophages
are derived from circulating monocytes. In healthy persons, circulating monocytes
contain no functional iNOS 16. In HIV infection 17, tuberculosis 18, Leishmania infection 19,
sepsis 20, alcoholic hepatitis/cirrhosis 21,22, rheumatoid arthritis 23, and Graves disease 24
circulating monocytes were found to be iNOS positive.
The purpose of this study was to determine whether circulating monocytes of
patients with IBD express iNOS and, if so, whether this expression is related to
disease activity. Considering the possible role of NO in monocyte activation we also




Thirty-three persons were included in this study, 18 healthy controls and 15
patients with active IBD: 4 patients with active Crohn’s disease (CD) and 11 patients
with active ulcerative colitis (UC). Active disease was defined as endoscopic and
histologic inflamed mucosa and an increased activity score. For CD, disease activity
was assessed using the Crohn’s Disease Activity Index (active disease was defined as
CDAI > 150)25. For UC, disease activity was assessed using a clinical activity score.
This score is based on the presence and intensity of eight key symptoms of UC, i.e.
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blood loss, mucoid discharge, frequency of defecation, consistency of faeces, tenesmus,
abdominal pain, rectal pain, and nausea/vomiting. Each symptom is scored from 0 to
2 points, resulting in a total score ranging from 0 (no symptoms) to 16 (all symptoms
present, most severe degree). A score of >4 was considered as active disease. All
patients had endoscopic and histologic inflamed mucosa at the time of the first
measurement. Because iNOS expression in circulating monocytes was studied in
relation to gut inflammation patients with extraintestinal manifestations were
excluded. Furthermore, none of the patients were pregnant or had cirrhosis,
malignancy, or rheumatic disease and none of them used azathioprine or ciclosporin
A at the time of inclusion. The patient characteristics are summarised in table 1. A
second measurement was performed in all 4 patients with active CD and 2 of the
patients with UC who went into remission as judged by their disease activity score.
At the time of the second measurement the medication was unchanged in 3 patients,
in 1 patient the prednisolon was stopped, in 1 patient the prednisolon was reduced
and azathioprine was added, and 1 patient had received prednisolon and azathioprine.
Table 1. Patient and control characteristics
Crohn’s disease Ulcerative colitis Healthy Controls
Number 4 11 18
Age * 38 (20-61) 50 (28-71) 31 (19-36)
Male/female 1/3 5/6 11/7
Smoking 2 0 4
Localization: Ileum (1) Proctitis (1)




a. Mesalazine (range) 3-5 g/day 2- 4 g/day
b. Prednisolon (mg/day) 20  (1 pt), 30 (1pt)   5 (1pt), 20 (2 pts),
40 (1 pt)  and 60 (1 pt)
Disease index * CDAI 258 (207-320) 7 (5-12)
CRP * 26 (0-201) mg/l 20 (0-192) mg/l
ESR * 35 (1-67) 28 (3-92)
Monocytes * 0.68 (0.3-1.1) 109/l 0.6 (0.2-6.6) 109/l
* median and range
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Monocyte isolation and stimulation
Circulating blood monocytes were isolated from patients and control subjects
using a non-activating method described before by Freundlich 26. Briefly, peripheral
blood mononuclear cells (PBMNC) were isolated by density gradient (Lymphoprep,
Nycomed Pharma AS, Oslo, Norway) centrifugation (20 minutes at 992 g) of
ethylenediaminetetraacetic acid (EDTA) anticoagulated blood. The PBMNC were
washed twice and resuspended at a concentration of 2-4 x 106 cells /ml in RPMI
1640 medium (Boehringer Ingelheim, Verviers, Belgium) containing 10 % v/v fetal calf
serum (FCS) (Gibco BRL Life Technologies, Breda, The Netherlands). The cells were
allowed to adhere to plasma treated gelatine coated culture flasks for 40 minutes at
37 °C, washed to remove non-adherent cells, and subsequently incubated with 10mM
EDTA, in phosphate buffered saline (PBS), pH 7.4, to recover adherent monocytes
(>90 % purity as checked by May-Grunwald-Giemsa staining).
For stimulation experiments, the monocytes were diluted to 1 x 106 cells/ml in
RPMI 1640 containing 10% v/v FCS and 0.06 mg/ml Gentamycin (Gibco BRL Life
Technologies, Breda, the Netherlands). Stimulation was performed in polystyrene
tubes with 500 U/ml IFN-γ (Boehringer Mannheim, Almere, The Netherlands) for 3
days at 37 °C in 5% CO2  humidified air. The mouse macrophage cell line RAW 264.7
(ATTC, Manassas, VA, USA) was used as a positive control for iNOS protein detection.
This cell line was stimulated for 24 h with 1 µg/ml LPS (E.coli, serotype 055:B5, Bio
Whittaker, Walkersville, MD, USA) and 200 U/ml IFN-γ (Boehringer Mannheim).
Immunocytochemistry
Cytospots of monocytes (1 x 105 cells/ml) were made by centrifugation (Shandon
Cytospin 2) at 32 g for 5 minutes. Cytospots were fixed in acetone for 10 minutes
at room temperature. For iNOS detection, a mouse IgG1 monoclonal antibody
(diluted 1/100) against amino acids 961-1144 of the C-terminus of mouse iNOS
(cat.No.N39120, Transduction Laboratories, Lexington, KY, U.S.A.) was used as
primary antibody. This antibody also recognises human iNOS. Endogenous peroxidase
activity was blocked by treatment with 0,075 % v/v H2O2 in PBS for 30 min. A mouse
IgG1 monoclonal antibody against Amyloid P Protein, diluted 1/100 (Novocastra
Laboratories, Newcastle-upon-Tyne, UK) served as negative control antibody. Peroxi-
dase-conjugated rabbit anti-mouse IgG was used as secondary antibody. Peroxidase
activity was developed with 0.2 mg/ml 3-amino-9-ethyl-carbazole (AEC) in sodium
acetate buffer containing 0.03 % v/v H2O2 for 10 minutes. Cytospots were
counterstained with Haematoxylin for 1 minute, washed with tap water and covered
with Kaiser’s glycerin-gelatin.
Western Blotting
Monocyte pellets were homogenised in a buffer containing 10 mmol/l Tris-HCl
(pH 7.2), 0.2 mmol/l phenylmethylsulfonylfluoride (PMSF), 1 mmol/l EDTA and 1
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mmol/l dithiothreitol. The protein concentration in the supernatant (crude lysate)
was determined by a Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA,
USA) using bovine serum albumin as protein standard. Aliquots of crude lysates
(100 µg) were boiled for 5 minutes, and separated on a 10% w/v sodium dodecylsulfate
polyacrylamide gel and transferred to nitrocellulose (Amersham International plc,
Buckinghamshire, UK), using a semi-dry blotting system according to the manu-
facturer’s instructions (Pharmacia, Uppsala, Sweden). Prestained molecular weight
standards (Bio-Rad) were used as marker proteins. The blots were incubated with
the monoclonal iNOS antibody diluted 1/100, in PBS containing 4% v/v skim milk
powder and 0.1% v/v Tween-20, consecutively followed by incubation with horse-
radish peroxidase labelled rabbit anti-mouse IgG (dilution 1/2000, DAKO A/S,
Glostrup, Denmark) and horse-radish peroxidase labeled swine anti-rabbit IgG
(dilution 1/2000, DAKO) and finally developed using an enhanced chemoluminescence
(ECL) Western blotting system (Amersham).
Flowcytometry
For flowcytometric analysis of circulating monocytes we used a whole blood
method in which in vitro activation of leukocytes is minimalised 27. Because iNOS is
associated with the peripheral cell membrane 28,29 this protocol, which is associated
with a mild permeabilization, could detect iNOS expression in monocytes. Using
this protocol iNOS expression was only slightly lower (data not shown) than results
obtained with a fixation and permeabilization protocol (Fix & Perm®, An der Grub
bioresearch GmbH;Kaumberg,Austria). EDTA anticoagulated blood was obtained
and kept on ice until sample preparation. Sample preparation was always started
within 10 minutes after blood sampling. All steps were performed in Hanks’ Balanced
Salt Solution (HBSS) without calcium and magnesium (Gibco BRL, Life Technologies
Ltd, Breda, The Netherlands), supplemented with 1% v/v Bovine Serum Albumin
(BSA, Boseral, Organon Teknika, Boxtel, The Netherlands). Cells were fixed with 1%
w/v paraformaldehyde in PBS for 10 minutes on ice, washed, and subjected twice to
erythrocyte lysis with lysis buffer (155mM NH4Cl, 10 mM KHCO3, 0.1 mM
Na2EDTA.H2O) for 5 minutes at 37 °C. For monocyte activation studies, IgG1
antibodies against CD11b (dilution 1/ 10) (Dako, Glostrup, Denmark), CD63 (dilution
1/10) (CLB-gran/12.435, CLB, Amsterdam, The Netherlands) and a phycoerythrin
labeled antibody against HLA-DR (dilution 1/10) (IgG2a antibody from Becton-
Dickinson, San Jose, CA, USA) were used. For iNOS detection, a IgG1 monoclonal
antibody, diluted 1/100, against iNOS (Transduction laboratories) was used. A mouse
IgG1 monoclonal antibody (dilution 1/100) against Amyloid P Protein served as
isotypical control antibody. The optimal concentration (1/50;1/100;1/200) of the
primary antibody was determined together with a concentration matched isotypic
control antibody in the first patients. Thereafter the optimal concentration (1/100)
of the iNOS antibody was used together with the same concencration of the isotypical
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control antibody. A sample without any antibody, and a sample with only the second
antibody, served as negative controls. The first antibody was incubated for one hour
at 4 °C. After washing, the cells conjugated with primary antibodies were incubated
with a goat anti-mouse Ig polyclonal antibody conjugated with Phycoerythrin
(Southern Biotechnology Associates Inc., Birmingham, AL, USA), diluted 1/20 in PBS
supplemented with 5 % v/v normal goat serum and 5% v/v normal human serum (in
order to prevent binding to the Fc receptor), for 30 min at 4 °C in the dark.
Subsequently, cells were washed and flowcytometric analysis was performed on a
Coulter Epics ELITE flowcytometer (Coulter, Hiaelea, FL, USA). In order to quantify
the fluorescence intensity of samples in terms of molecules of equivalent soluble
fluorochromes units (MESF), Quantum 1000 beads (Flow Cytometry Standards Corp,
San Juan, PR, USA) were used to calibrate the flowcytometer. Data were analysed
using WinList software (Verity Software House Inc, Topsham, ME, USA). The expression
of surface markers was calculated as a fluorescence index (FI):
FI   =                MESF sample - MESF irrelevant antibody
                             MESF irrelevant antibody
The percentage of positive cells was calculated as the % positive cells minus %
positive cells incubated with irrelevant antibody.
Neopterin and Nitrite/Nitrate assays
Neopterin ELISA: Levels of neopterin, a plasma marker for monocyte activation,
were measured using a commercially available ELISA (Brahms Diagnostica, Berlin,
Germany).
Nitrite/Nitrate levels: The stable end products of NO, nitrite and nitrate (NOx)
were measured in plasma according to the method described by Moshage et al30 .
Statistical Analysis
Data are represented as the median + range. Differences between groups were
analysed by the Mann-Whitney-U test. A two-tailed p-value <0.05 was considered
to indicate statistical significance. Differences between paired observations were
analysed using the Paired Wilcoxon test. Correlation between parameters was
analysed by the Spearman rank correlation test.
RESULTS
iNOS protein expression in isolated monocytes
As detected by immunocytochemistry, unstimulated macrophages from the mouse
RAW 264.7 cell line and unstimulated human monocytes from healthy controls
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Figure 1. Detection of iNOS expression by immunocytochemistry on cytospots of stimulated and
unstimulated monocytes. (A) unstimulated mouse macrophages showed no iNOS expression. (B) mouse
macrophages stimulated with IFN-γ and LPS for 1 day showed intense iNOS staining. (C) unstimulated
human monocytes isolated from a healthy control subject showed no iNOS staining after 3 days of
culture. (D) human monocytes isolated from a healthy control subject  stimulated with IFN-γ (500 U/ml)
for 3 days showed iNOS staining. (E) freshly isolated monocytes from a patient with active Crohn’s
disease showed  weak iNOS staining (arrows). (F) Staining was absent when an irrelevant antibody was
used as primary antibody. (G)  monocytes isolated from a patient with active Crohn’s disease and cultured
for 1 day without stimulation showed clear iNOS staining. (H) ) Staining was absent when an irrelevant
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showed no iNOS expression after 1 and 3 days in culture (figure 1A and C
respectively). Mouse macrophages showed intense iNOS staining after 1 day of
stimulation with IFN-γ and LPS (figure 1 B). Isolated human monocytes from healthy
controls showed iNOS expression after 48h stimulation (data not shown) and was
clearly demonstrated after 3 days of stimulation with IFN-γ (figure 1D). Freshly
isolated monocytes from patients with active IBD, showed a weak expression of
iNOS (figure 1E). No staining was observed after incubation with an irrelevant anti-
body (figure 1F). Culturing these cells for 24 h without stimulation, enhanced the
expression of iNOS (Fig 1G). Staining was absent when the irrelevant antibody was
used as primary antibody (figure 1H).
The expression of iNOS protein was confirmed by Western blot analysis. The
mouse IgG1 monoclonal antibody recognised a single protein of approximately 130
kDa in crude lysates of LPS/IFN-γ stimulated RAW 264.7 mouse macrophages (Figure
2, lane 1) and in monocytes from healthy controls after 3 days stimulation with IFN-γ
(Figure 2, lane 3). Human monocytes from healthy controls showed no iNOS
expression after 3 days of culture without IFN-γ stimulation (Figure 2, lane 2).
However, freshly isolated monocytes from a patient with active Crohn’s disease
showed iNOS expression (Figure 2, lane 4).
Figure 2. Immunodetection on Western blots of crude lysates from monocytes. Lane 1:  50 µg protein
of mouse macrophages stimulated for 1 day with IFN-γ and LPS. Lane 2: 100 µg protein of unstimulated
monocytes from a healthy control subject after 3 days culture. Lane 3: 100 µg protein  of  monocytes
from a healthy control subject after 3 days stimulation with IFN-γ.  Lane 4: 100 µg protein from freshly
isolated monocytes from a patient with active Crohn’s disease.





































Flowcytometric detection of iNOS
Flowcytometric analysis of circulating monocytes from patients with active IBD
revealed a significant increase (p = 0.02) in iNOS expression (FI = 1.3, range 0.1-6.3)
compared to healthy controls (FI = 0.8, range 0.0-1.8 (Figure 3.A.). The percentage
of iNOS positive monocytes (37.3 %, range 1.0-77.0) was increased (p=0.005) in
patients with active IBD compared to healthy controls (5.3 %, range 0.0-43.3) (Figure
3.B.). Analysis of the CD patients showed that both the iNOS expression (FI=
3.1,range 1.1-6.3 vs 0.8, range 0.0-1.8, p = 0.009) and percentage of iNOS positive
monocytes (62.0 %, range 37.3-76.4 vs 5.3 %,range 0.0-43.3, p = 0.004) were increased
compared to controls. In CD patients, neither the fluorescence index nor the per-
centage of iNOS positive monocytes did correlate with the CDAI score. For UC
patients, the percentage of positive monocytes was higher than in controls (17.5 %,
range 1-77.0 vs 5.3 %, range 0.0-43.3, p = 0.04). For this subgroup, iNOS expression
was not different compared to controls (FI= 1.2, range 0.2-3.0 vs 0.8, range 0.0-1.8,
p = 0.14)). In UC patients, neither the fluorescence index nor the percentage of
iNOS positive monocytes did correlate with the disease activity score. There was






























Figure 3.A. Difference in iNOS
fluorescence index (FI) of monocytes
from 18 healthy controls (median FI
0.8,range 0.0-1.8) and 15 patients
with IBD (Crohn’s disease ( ),
ulcerative colitis ( ), median FI
1.3,range 0.1-6.3 as detected by
flowcytometry.
Figure 3.B. Difference in percentage
of iNOS positive monocytes from 18
healthy controls (median 5.3, range
0.0-43.3) and 15 patients with IBD
(Crohn’s disease (  ) ,ulcerative colitis
(  ), median 37.3,range 1.0-77.0) as
detected by flowcytometry.
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circles) or UC (Figure 3 A & B open circles) patients. In addition, there was no
difference between patients taking steroids (FI= 1.1, range 0.2-2.0; % iNOS positive
cells: 49.7 %,range 1-74.4) or not taking steroids (FI= 2.5, range 0.1-6.3; % iNOS
positive cells: 36.3 %, range 1.0-77.0 ). No iNOS expression was detected in circulating
lymphocytes or granulocytes from IBD patients or controls.
Analysis of paired data showed that both the iNOS expression(p=0.03) and the
percentage of iNOS positive monocytes (p=0.03) were higher in IBD patients with

























































Figure 4.A. Fluorescence index for
iNOS expression as detected by
flowcytometry in monocytes from 4
patients with Crohn’s disease  (  ) and
2 patients with ulcerative colitis ( )
during active disease and during
remission.
Figure 4.B. Percentage of iNOS
positive monocytes  as detected by
flowcytometry from 4 patients with
Crohn’s disease (  ) and  2 patients with
ulcerative colitis ( ) during active
disease and during remission.
Flowcytometric analysis of monocyte activation
Surface markers for monocyte activation CD63 and CD11b were not elevated
on circulating monocytes of patients with active IBD (Table 2). Analysis of paired
data showed that the CD63 and CD11b expression in patients with active disease
was not different from expression in the same patients after achieving remission.
The percentage of HLA-DR positive monocytes was decreased in IBD patients
compared to healthy controls (Table 2). Subgroup analysis showed that this decrease
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Correlation with plasma C-reactive protein, neopterin and nitrite/nitrate levels
The iNOS fluorescence index (r=0.6, p=0.03) and percentage of iNOS positive
monocytes showed a weak correlation with C-reactive protein levels (r=0.5, p=0.04).
The levels of neopterin in IBD patients (12.6, range 5.2-23.8 nmol/l) were significantly
higher (p= 0.002) than in healthy controls (6.3, range 4.7-12.7 nmol/l), but neopterin
levels were not correlated with the iNOS expression in circulating monocytes.
Although 3 patients with IBD had elevated plasma nitrite/nitrate levels (>50 µmol/l)
there was no significant difference between levels in IBD patients (37, range 23-104
µmol/l) and controls (31, range 18-58 µmol/l).
DISCUSSION
Tissue macrophages in inflamed mucosa from patients with active IBD are
activated and express iNOS 10,11. Tissue macrophages are derived from circulating
monocytes. In this study we provide evidence that circulating monocytes from patients
with active IBD express iNOS but are not otherwise activated. Furthermore, we
found that the iNOS expression in circulating monocytes is related to disease activity.
There is increasing evidence that iNOS can be induced in human macrophages/
monocytes31-33, but the induction occurs slower and the amount of NO produced is
lower than in rodent macrophages/monocytes 34. Indeed, we could detect iNOS in a
large percentage of circulating monocytes from patients with active IBD; however,
the amount of iNOS per cell (fluorescence index) was low. The end products of NO
Table 2. Monocyte activation markers
Fluorescence index Percentage of positive monocytes
Marker IBD patients Controls IBD patients Controls
N=15 N=18 N=15 N =18
CD 63 8.3 (3.4-44.3) 7.5 (2.6-20.5) 94.3 (39.3-97.6) 92.7 (67.7-96.5)
CD 11b 35.6 (22.1-174.2) 38.3 (20.1-83.8) 95.1 (39.9-98.7) 95.3 (90.4-98.7)
HLA-DR 14.7 (3.7-86.3) 17.4 (6.8-75.4) 89.5 (67.3-95.8) 92.2 (81.3-95.8)*
* p  < 0.05 control vs IBD
was mainly due to a decreased percentage of HLA-DR in UC patients. Analysis of
paired data showed that neither the fluorescence index nor the percentage of HLA-
DR positive monocytes was different between patients with active disease and the
same patients in remission.
51
IN O S  I N  C I R C U L A T I N G  M O N O C Y T E S  I N  I B D
synthesis, nitrite and nitrate, were elevated in only 3 out of 15 patients with active
IBD and no correlation between iNOS expression in circulating monocytes and
plasma nitrite/nitrate levels was found. Therefore, iNOS in circulating monocytes
probably does not produce high amounts of NO. It is possible that human monocytes
are not able to produce large amounts of NO because they produce not enough
5,6,7,8-tetrahydro-L-biopterin (BH4), an essential co-factor for iNOS activity 35.
Alternatively, although the mouse and human iNOS gene share 80 % homology in
their coding sequences, homology in their promoter regions is only 60 % 36-37. This
difference may account for the less rapid induction of iNOS in human monocytes/
monocytes.
Interestingly, the expression of iNOS was reduced in patients who went into
remission. Patients in remission had lower levels of CRP and neopterin. The pro-
inflammatory cytokines TNF-α, IFN-γ, and IL-1 are the main inducers of iNOS, whereas
the anti-inflammatory cytokines IL-4, IL-10, IL-13, and TGF-β are the main suppressor
cytokines of iNOS induction 38. It is known that proinflammatory cytokines are
downregulated and anti-inflammatory cytokines are upregulated during remission 39.
A relation between the presence of proinflammatory cytokines and iNOS in
circulating monocytes is supported by a correlation between iNOS expression and
CRP levels. Although the group of patients who went into remission was small, the
significantly reduced expression of iNOS in circulating monocytes indicates that it
perhaps can be used as a disease activity marker.
Recruitment of circulating monocytes and T cells to the inflamed mucosa plays
a key role in the pathogenesis of IBD 40-41. The data on the functional changes of
circulating monocytes in IBD are conflicting. Isolated monocytes from patients showed
an increased production of cytokines 42 and reactive oxygen species 3 upon stimulation
in vitro. We showed here that isolated monocytes from patients with active IBD, in
contrast to monocytes from healthy controls, spontaneously express iNOS after 1
day of culture, without stimulation. However, we found no evidence for activation of
circulating monocytes from patients with active IBD. For example, the CD63 mole-
cule, a marker for monocyte and neutrophil activation, 43,44 was not increased on
circulating monocytes and in agreement with Greenfield 45, we found no upregulation
of the CD11b adhesion molecule on circulating monocytes from patients with active
IBD.
Although these findings support the idea that circulating monocytes in active
IBD are not activated, we did find an increase in plasma neopterin levels. Neopterin
is produced by both circulating monocytes and activated tissue macrophages.Therefore,
the increased levels of neopterin may have been derived from activated tissue
macrophages. The expression of surface markers of monocyte activation reflects
the state of activation of circulating monocytes only.
What could be the role of NO production in circulating monocytes from patients
with active IBD? It is clear that in rodents NO is involved in macrophage mediated
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killing of (intracellular) microorganisms and tumour cells 32. The course of an infection
or inflammation in mice lacking the iNOS gene is aggravated compared to the wild
type mice 46. Apart from its role in macrophage cytotoxicity, there is evidence that
NO is involved in immunoregulation. For example, production of NO is one
mechanism by which activated mouse macrophages can restrict T cell expansion47
and IFN-γ production by human T-lymphocytes 48. A differential susceptibility to NO
has been described for murine Th1 and Th2 cells 49, but a preferential inhibition of
Th1 cytokine secretion by NO was not found in human T cells 50. NO may inhibit
monocyte/macrophage function by inhibiting cytokine 51,7 and chemokine 52,53
production, phagocytic activity 54 , and respiratory burst 55. Interestingly, NO can also
downregulate the HLA-DR expression on monocytes/macrophages 56. In the pre-
sent study we found a decreased HLA-DR expression on circulating monocytes
from patients with active UC , as was also previously reported 57. Therefore, NO
may perhaps inhibit monocyte activation.
Recently a frameshift mutation in the NOD2 gene was associated with
susceptibility to Crohn’s disease but not to ulcerative colitis 58,59. NOD2 is restricted
to monocytes and the frameshift mutation can lead to a truncated protein not able
to activate NF-κB in monocytes in respons to bacterial lipopolysaccharides 60. Because
iNOS is a NF-κB mediated protein patients with Crohn’s disease who do not express
iNOS could be the patients with this mutation. Furthermore it would be interesting
to relate this mutation and the iNOS expression in peripheral monocytes to the
occurence of extraintestinal manifestations.
In conclusion, this study shows that iNOS is expressed in circulating monocytes
from patients with active IBD and is related to disease activity. Considering the
absence of systemic monocyte activation markers, NO may have a function in
preventing systemic monocyte activation and thus may modulate disease activity in
extra-intestinal sites in patients with active IBD.
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ABSTRACT
Background: Inducible Nitric Oxide Synthase (iNOS) is expressed in intestinal
epithelial cells (IEC) of patients with active inflammatory bowel disease (IBD) and in
IEC of endotoxemic rats. The induction of iNOS in IEC is an element of a NF-κB
mediated survival pathway. However this pathway could be blocked during oxidative
stress. Heme oxygenase 1 (HO-1) is an AP-1 regulated gene that is induced by
oxidative stress. The enzyme produces carbon monoxide (CO) which may attenuate
the inflammatory response.
Aim: Since iNOS and HO-1 are potential therapeutic targets in IBD and sepsis
we studied the regulation of these enzymes in response to inflammation and oxidative
stress.
Methods: In endotoxemic rats (in vivo model) the thiol-modifying agent
diethylmaleate (DEM) and in human colon carcinoma cells DLD-1 (in vitro model)
both DEM and the lipid peroxidation end product 4-hydroxynonenal (4-HNE) were
used to induce oxidative stress.  Rats were treated with DEM 0.5 hr before and 3
hrs after LPS injection (5mg/kg ip) and sacrificed 6 hr after LPS injection. DLD-1
human colon carcinoma cells were exposed to a cytokine mix (CM) for 8 hr. DEM
or 4-HNE were added 0.5 hr prior to and 4 hr after addition of CM. HO-1 and iNOS
expression was evaluated by RT-PCR , Western blot and immunohistology. NF-κB
activation was evaluated by EMSA.
Results: LPS induced iNOS but not HO-1 in IEC of the ileum and colon. DEM-
induced oxidative stress strongly induced HO-1 both in epithelial and inflammatory
cells. Combined treatment with LPS and DEM decreased iNOS expression but
strongly induced HO-1 expression. Similarly, cytokine mix induced iNOS but not
HO-1 in DLD-1 cells. DEM and 4-HNE treatment prevented iNOS induction in a
NF-κB dependent manner but increased the HO-1 expression in CM-exposed DLD-1
cells.
Conclusion: We demonstrate an opposite regulation of iNOS and HO-1 in
intestinal epithelial cells in response to cytokine exposure and DEM or 4-HNE
induced oxidative stress. These findings suggest that iNOS (NF-κB driven) and HO-1
(AP-1 driven) represent mutual exclusive survival mechanisms in intestinal epithelial
cells.
INTRODUCTION
A monolayer of intestinal epithelial cells (IEC’s) forms a selective barrier in the
gastrointestinal tract. During acute or chronic inflammation this barrier is
compromised due to exposure to reactive oxygen species (ROS) and/or cytokines.
A number of non-enzymatic (e.g. glutathione, flavonoids and vitamins A, C and E) as
well as enzymatic scavengers of ROS (e.g. superoxide dismutases, catalase, and
59
IN O S  A N D  H O - 1  E X P R E S S I O N  I N  I N T E S T I N A L  I N F L A MM A T I O N
glutathione peroxidase) prevent the accumulation of ROS. Unfortunately, these
defense mechanisms are not always adequate to counteract the toxic effects of
ROS, resulting in what is termed a state of oxidative stress. The enzyme heme
oxygenase-1 (HO-1), which generates carbon monoxide (CO), is induced by oxidative
stress. HO-1 detoxifies the pro-oxidant heme into CO, Fe and biliverdin 1. The latter
is subsequently converted into bilirubin, a potent anti-oxidant. In addition, the HO-1
product CO has been reported to have anti-inflammatory and anti-apoptotic effects 2.
The enzyme inducible nitric oxide synthase (iNOS) that generates nitric oxide (NO)
is induced by inflammatory cytokines. NO has an important role in maintaining
mucosal integrity under normal and pathological conditions. In normal conditions,
small amounts of NO produced by endothelial NOS (eNOS) maintains blood supply
to the gastrointestinal mucosa. In inflammatory conditions, large amounts (micro
molar) of NO are produced by iNOS. It has been demonstrated that intestinal
epithelial cells express iNOS during inflammatory conditions such as celiac disease 3,
inflammatory bowel disease (IBD) 4-7, diverticulitis 5, and endotoxemia 8. The exact
role of iNOS-derived NO in these conditions is unknown. In endotoxemia
overproduction of NO may contribute to epithelial dysfunction. Selective inhibition
of iNOS reduced hyperpermeability and bacterial translocation in endotoxemic rats 9.
The HO-1 gene is predominantly regulated by the oxidative stress responsive
transcription factor AP-1, whereas iNOS is predominantly regulated by the
inflammation-activated transcription factor NF-κB. Cross talk in the regulation of
these enzymes exists, e.g. NO is a potent inducer of HO-1 and CO can decrease
NO production 10. In inflammatory conditions, inflammation and oxidative stress
usually occur together. In the present study we have investigated the regulation of
HO-1 and iNOS genes and their products in LPS-induced endotoxemia and in cytokine
activated human colon carcinoma cells, both in the presence and absence of additional
oxidative stress. We demonstrate an opposite regulation of iNOS and HO-1 in
inflammation and oxidative stress. These findings suggest that iNOS (NF-κB driven)
and HO-1 (AP-1 driven) represent mutual exclusive survival mechanisms in intestinal
epithelial cells.
MATERIAL AND METHODS
In vivo endotoxemia model
Specific pathogen-free male Wistar rats (200-250g; purchased from Harlan-CPB,
Zeist, The Netherlands) were kept at the Central Animal Laboratory of the University
of Groningen under routine conditions and had free access to drinking water and
standard chow. The local committee for care and use of laboratory animals approved
the study.  Rats were injected intraperitoneally at t=0 hr with 5 mg/kg endotoxin
(LPS: E. coli serotype 0127:B8; Sigma Chemical Co, St.Louis, MO) with (n=6) or
without (n=6) intraperitoneal administration of 4 mmol/kg diethylmaleate (DEM)
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dissolved in olive oil (1:1 vol/vol; Sigma Chemical Co, St Louis, MO) at t= -0,5 hr and
t=3 hr. DEM is an oxidative stress inducing alkylating agent which rapidly depletes
reduced glutathione11. Two additional groups of rats received only PBS (n=6) or
DEM (n=6) at 4 mmol/kg. Six hours after LPS injection rats were anaesthetized with
pentobarbital (60 mg/kg, IP) and sacrificed. Blood was collected by cardiac puncture
and colon and ileum were removed. For routine histology, tissue specimens were
fixed by immersion in 4% buffered paraformaldehyde and embedded in paraffin. For
immunohistochemistry tissue specimens were snap-frozen in isopentane. For Western
blotting and RNA isolation, tissue specimens were snap frozen in liquid nitrogen
and stored at –80C.
Cell culture experiments
The commonly used human colon carcinoma cell-line DLD-1 was used for in
vitro experiments. Cells were cultured in a humidified incubator at 37° C in 5% CO2
in Dulbecco’s Modified Eagle’s Medium (DMEM, Boehringer Ingelheim, Verviers,
Belgium) supplemented with glutamax, 10 % v/v fetal calf serum (Gibco BRL, Breda,
the Netherlands), penicillin (50 U/ml), streptomycin (50 µg/ml) and fungizone (5 µg/ml).
To mimic the pathophysiologic situation of inflammation in vitro, DLD-1 cells were
stimulated for 6 hours with a cytokine mix (CM) composed of 20 ng/ml human
interleukin-1β (IL-1β), 1000 U/ml human interferon-γ (IFN-γ) and 10 ng/ml human
tumor necrosis factor-α (TNF-α). DEM at 1mmol/L was added 30 min before and
3,5 hr after stimulation with CM. DLD-1 cells were also exposed to the lipid
peroxidation end product 4-hydroxy-nonenal (4-HNE). NF-κB activation was blocked
using the proteasome inhibitor MG-132 at 52 nmol/L added at 30 min before and
3,5 hr after stimulation with CM.
Immunohistochemistry
For immunohistochemistry, 4 µm cryostat sections were cut, dried and fixed in
acetone for 10 min at room temperature. For iNOS detection a rabbit polyclonal
antibody developed in our laboratory was used 11. For HO-1 detection a monoclonal
antibody (OSA-111) from Stressgen (Victoria, BC, Canada) was used. Slides were
incubated with the polyclonal iNOS antibody (1:300) or monoclonal HO-1 anti-
body (1:500) in PBS containing 1% BSA for 60 min at room temperature. Subsequently,
endogenous peroxidase activity was blocked by incubating for 30 min in PBS containing
0,075% H2O2. For iNOS detection, peroxidase conjugated goat anti-rabbit Ig (1:50
and peroxidase conjugated rabbit anti-goat Ig (1:50) and for HO-1 detection
peroxidase conjugated rabbit anti-mouse Ig (1:50) and peroxidase conjugated rabbit
anti-mouse Ig (1:50) all from Dako (Glostrup, Denmark) were used as secondary
and tertiary antibodies. Color was developed using 3-amino-9-ethylcarbazole (10mg/
2.5mL dimethylformamide in 50 ml 0.1 mol/L acetate buffer pH 5.0) containing
0,03% H2O2 for 10 minutes at room temperature. Counterstaining was performed
with haematoxylin, and the slides were covered with Kaiser’s glycerin-gelatin.
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Western blot analysis
Ileum and colon samples were homogenized with a Polytron homogenizer
(Kinematica GmbH, Luzern,Switzerland) in an extraction buffer containing 20 mmol/L
Tris HCL (pH 7.2, 4 °C), 0.2 mmol/L phenyl-methylsulfonyl fluoride, 1 mmol/L ethyl/
enediaminetetraacetic acid and 1 mmol/L dithiothreitol. DLD-1 cells were harvested
in the same extraction buffer. After centrifugation (30 min, 11,600 g), the protein
concentration in the supernatant (crude lysates) was determined with the Bio-Rad
protein assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin as
standard. The crude lysates were fractionated on a 10% sodium dodecylsulfate
polyacrylamide gel and transferred to nitrocellulose (Amersham International plc,
Buckinghamshire, UK), using a semi-dry blotting system according to manufacturer’s
instructions (Pharmacia, Uppsala, Sweden). Prestained molecular weight standards
(Bio-Rad) were used as marker proteins. For iNOS detection on rat samples a
polyclonal antibody was used 11 and for detection of iNOS on human samples (DLD-1
cells), a monoclonal iNOS antibody (cat. # N39120, Transduction Laboratories,
Lexington, KY, USA) were used. For HO-1 detection a polyclonal antibody (SPA-
896) from Stressgen (Victoria, BC, Canada) was used. Antibodies were diluted in
PBS containing 4% skim milk powder and 0.1% Tween-20, subsequently incubated
with the appropriate peroxidase labeled Ig (dilution 1:2000) and finally developed
using the ECL Chemiluminiscence detection reagents (Amersham).
RNA isolation and reverse-transcriptase polymerase chain reaction (RT-PCR)
RNA was isolated from tissue specimens and cell layers using Trizol reagent
(Life Technologies Ltd) according to manufacturer’s instructions. Reverse transcription
was performed on 5 µg of total RNA using random primers in a final volume of 75
µl (Reverse Transcription System, Promega, Madison, WI). Polymerase chain reaction
(PCR) on cDNA was performed with Taq polymerase (Eurogentec, Seraing, Belgium).
The primer set for human iNOS  was sense: 5'-CTA TGC TGG CTA CCA GAT GC-
3', antisense: 5'-CCA TGA TGG TCA CAT TCT GC-3' and for rat iNOS  sense: 5’-
CGA GGA GGC TGC CCT GCA GAC TGG-3’; antisense: 5’-CTG GGA GGA
GCT GAT GGA GTA GTA-3’, resulting in amplified products of  505 bp and 1383
bp respectively. The primer set for human HO-1 was sense: 5’- ACA TCT ATG TGG
CCC TGG AG – 3’ , antisense: 5’- TGT TGG GGA AGG TGA AGA AG – 3’ and for
rat HO-1 sense: 5’- CAC GCA TAT ACC CGC TAC CT –3’, antisense: 5’- AAG
GCG GTC TTA GCC TCT TC – 3’, resulting in amplified products of 348 bp and
227 bp respectively. Primers specific for glyceraldehyde-3-phosphate dehydrogenase28
(GAPDH, sense: 5’-CCA TCA CCA TCT TCC AGG AG-3’; antisense 5’-CCT GCT
TCA CCA CCT TCT TG-3’), resulting in an amplified product of 576 bp, were used
as control for the RT-PCR procedure. The tubes were incubated in a GeneAmp PCR
system 2400 (Perkin-Elmer, Norwalk, CT) at 95°C for 5 minutes to denature the
primers and cDNA. The cycling program was 95°C for 40 seconds (iNOS) or 30
seconds (HO-1 and GAPDH), 60°C for 40 seconds (iNOS) or 30 seconds (HO-1
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and GAPDH), 72°C for 40 seconds (iNOS) or 30 seconds (HO-1 and GAPDH), and
for 5 minutes in the last cycle, and comprised 30 cycles for both iNOS primer sets,
28 cycles for the human HO-1 primer set, 26 cycles for the rat HO-1 primer set and
22 cycles for the GAPDH primer set.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts of cultured DLD-1 cells were prepared using a final concen-
tration of Nonidet P-40 of 0.25%. EMSA for NF-κB was performed as described
previously 12. Equal amounts of nuclear extract protein were used for EMSA.
RESULTS
Expression of iNOS and HO-1 in endotoxemic rats
In the normal ileum (fig 1A) and colon (data not shown) iNOS is only expressed
in some inflammatory cells scattered throughout the lamina propria (fig 1A). Treatment
with DEM did not change this expression pattern (fig 1B). Six hours after LPS admini-
stration, rat ileum displayed a diffuse and intense epithelial iNOS expression (fig 1C)
whereas rat colon displayed focal epithelial iNOS expression (data not shown).
Epithelial iNOS expression in the ileum was both in the crypts, along the crypt axis
and abundant in the villus whereas in the colon the iNOS expression was confined
to crypt epithelial cells. The expression of iNOS in inflammatory cells was not altered
in the endotoxemic gut. Epithelial iNOS expression was almost completely abolished
in endotoxemic rats treated with the oxidative stress inducing agent DEM (fig 1D),
only low expression in some crypt cells was left (fig 1D,arrow). DEM treatment did
not change iNOS expression in inflammatory cells of endotoxemic rats. RT-PCR
analysis confirmed the immunohistochemistry results (fig 2).
In the normal ileum (fig 1E) and colon (data not shown) HO-1 is only expressed
in some inflammatory cells scattered throughout the lamina propria (fig 1E). HO-1
expression was strongly induced in both the ileum (fig 1F) and colon (data not
shown) of normal non-endotoxemic rats treated with the oxidative stress-inducing
agent DEM. The HO-1 expression was present in the epithelial cells in the inter-
mediate part of the crypt-villus axis and in inflammatory cells. Six hours after LPS
administration, rat ileum displayed only focal HO-1 expression in leukocyte aggregates
(fig 1G). This focal expression of HO-1 in leucocytes was not seen in the rat colon
(data not shown). No epithelial HO-1 expression was seen in the endotoxemic gut.
In endotoxemic rats treated with DEM, the induction of HO-1 expression was even
higher then in the non-endotoxemic rats treated with DEM alone. Both in the ileum
(fig 1H) and colon a strong HO-1 expression was seen in epithelial cells of the
crypts and the intermediate part of the crypt-villus axis together with a massive
influx of HO-1 positive inflammatory cells in the lamina propria. RT-PCR analysis
confirmed the immunohistochemistry (fig 2).
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Figure 2. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of HO-1 and iNOS of whole
rat ileum tissues samples using GAPDH as a control housekeeping gene. In rats treated with PBS alone
HO-1 and iNOS mRNA was undetectable. Induction of oxidative stress with diethylmaleate (DEM, 4mmol/kg
ip 0,5hr before and 3 hr after PBS injection) induced HO-1 mRNA but not iNOS mRNA. Six hours after
LPS injection (5 mg/kg ip) HO-1 mRNA was not induced, in contrast iNOS mRNA was markedly induced.
Combined treatment with LPS and DEM markedly induced HO-1 mRNA. In contrast it completely abolished





Figure 3. Reverse transcription-polymerase chain reaction (RT-PCR) analysis (3A) and Western blot analysis
(3B) of HO-1 and iNOS of unstimulated and cytokine-stimulated human DLD-1 coloncarcinoma cells
(duplex samples). Unstimulated control DLD-1 cells showed a small amount of HO-1 mRNA but no iNOS
mRNA. Induction of oxidative stress with diethylmaleate (DEM, 1mmol/l) or the lipid peroxidation end-
product 4-hydroxy-nonenal (4-HNE, 100 µmol/L) or treatment with the NF-κB (proteasome) inhibitor
MG-132 (52 nmol/l) induced HO-1 mRNA. In contrast these agents did not induce iNOS mRNA. Treatment
with a cytokine mix (CM, IL-1β 20 ng/ml, TNF-α 10 ng/ml, IFN-γ 1000 U/ml) induced iNOS mRNA (3A)
and protein (3B) but did not change the HO-1 mRNA expression (3A). Combined treatment with CM
and DEM, 4-HNE or MG-132 did not change HO-1 mRNA induction compared to the unstimulated cells.
In contrast combined treatment with CM and DEM or 4-HNE completely prevented the induction of
iNOS mRNA (3A) and protein (3B). Combined treatment with CM and MG-123 reduced iNOS mRNA
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Regulation of iNOS and HO-1 in DLD-1 colon carcinoma cells
Cytokine mix (CM) induced iNOS mRNA and protein expression in DLD-1
cells (fig 3A&B). CM-induced iNOS expression was abolished by simultaneous
treatment with the oxidative stress-inducing agent DEM (fig 3A&B). Like DEM, 4HNE,
a lipid peroxidation end product generated during oxidative stress, inhibited cytokine-
induced iNOS expression (fig 3A&B). Finally, the proteasome inhibitor MG-132,
used as an NF-κB inhibitor, inhibited iNOS expression (fig 3A&B). The inhibition of
iNOS expression by DEM, 4HNE and MG-132 correlated with inhibition of NF-kB
activation determined by EMSA (fig 4A&B), showing that iNOS is an NF-κB regulated
gene and indicating that DEM and 4HNE inhibit iNOS expression via inhibition of
NF-κB activation. 4HNE and DEM in the absence of CM did not induce iNOS mRNA
or protein expression (fig 3A). HO-1 mRNA was almost not expressed in control
and CM-treated DLD-1 cells. HO-1 mRNA expression was strongly induced in DLD-1
cells treated with DEM, 4HNE and MG-132. Induction of HO-1 mRNA by DEM,
4HNE or MG-132 was not changed by the simultaneous treatment with CM (fig
3A). These results confirm the in vivo data and demonstrate that iNOS and HO-1
are reciprocally regulated by cytokines and oxidative stress.
Figure 4. Electrophoretic Mobility Shift Assay (EMSA) for NF-κB binding activity on nuclear extracts of
cytokine-stimulated human DLD-1 coloncarcinoma cells (duplex samples). Nuclear extracts from cytokine
mix (CM, IL-1β 20 ng/ml, TNF-α 10 ng/ml, IFN-γ 1000 U/ml) stimulated DLD-1 cells showed NF-κB activity
(4A). This activity was completely absent in nuclear extracts from CM stimulated cells that were exposed
to oxidative stress using diethylmaleate (DEM, 1 mmol/l) or the proteasome inhibitor MG-132 (52 nmol/l)
(4A). Furthermore, the lipid peroxidation end product 4-hydroxy-nonenal (4-HNE) dose dependently
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DISCUSSION
In this study we show that iNOS is induced in intestinal epithelial cells by cytokines
both in vivo (endotoxemia) and in vitro (cytokine mix). In contrast, oxidative stress
with or without inflammation or cytokines did not induce this enzyme. In fact,
oxidative stress inducesd by DEM or 4-HNE abolishes cytokine-induced iNOS
induction in intestinal epithelial cells. DEM is a non-physiologic electrophilic agent
that complexes with GSH via the transferase reaction and can modify thiol groups.
DEM has been proposed as a therapeutical agent to prevent organ damage in
inflammatory conditions 13 but its use was restricted by toxicity 14 which could be a
consequence of its alkylating reactivity and/or its reactivity with cysteine residues
leading to loss of protein function. It may be able to react with thiol groups in NF-
κB thus reducing its activity. 4-HNE is an important physiologic lipid peroxidation
derived aldehyde generated during oxidative stress. The EMSA data show that 4-
HNE dose dependently prevented NF-κB activation in intestinal epithelial cells. Ji et
al 15 demonstrated that 4-HNE inhibits IκB kinase activity and subsequent
phosphorylation of IκBα, whereas Parola et al have demonstrated in hepatic stellate
cells that 4-HNE directly interacts with c-Jun amino-terminal kinases (JNKs), leading
to the activation of the transcription factor AP-116 Therefore, 4-HNE is probably an
important endogenous factor that regulates NF-κB activation during inflammatory
conditions associated with oxidative stress.
In contrast, HO-1 is not induced in intestinal epithelial cells by either inflammation
or cytokines. In contrast to iNOS, HO-1 is hardly expressed in the ileum and colon
of LPS-treated rats. HO-1 is strongly induced by various forms of oxidative stress,
including superoxide anions, hydrogen peroxide, DEM and the lipid peroxidation
end-product 4HNE. Indeed, DEM-treatment alone strongly induced HO-1 expression
in ileum and colon whilst the induction of HO-1 was maximal in rats treated with a
combination of DEM and LPS. This is in accordance with HO-1 being an oxidative
stress inducible, AP-1 regulated gene 17 that has only a weak NF-κB binding site 18;19.
The induction of HO-1 in intestinal epithelial cells by oxidative stress may serve
a protective function. HO-1 overexpression by gene transfer protects organs against
oxidative stress-induced injury 20. Inhibition of HO-1 with tin mesoporphyrin (SnMP)
showed an increased damage in experimental colitis 21. The products of the enzyme
HO-1 can act as anti-oxidant (bilirubin) and anti-inflammatory agents (carbon
monoxide). Manipulation of the HO-1 activity therefore might be of interest as a
new treatment option to treat inflammatory bowel disease.
In endotoxemic rats, we observed a more pronounced iNOS expression in the
ileum than in the colon. Morin et al showed that in the intestine iNOS mRNA is
already induced 1 hour after injection of LPS 8. Like our results, they observed a
more prominent induction of iNOS in the ileum than in the colon and the jejunum.
The same group showed that epithelial iNOS expression was more prominent in
female and older rats, indicating an age and gender dependent responsiveness to
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LPS 22. If such a massive iNOS induction and NO production in intestinal epithelial
cells along the axis of the intestinal tract is also present in human endotoxemia it
must have implications for intestinal function. Indeed intestinal permeability is
increased in human volunteers injected with LPS 23 and in septic patients 24. Unno 9
showed that selective inhibition of iNOS reduces intestinal hyperpermeability and
bacterial translocation in endotoxemic rats. Several animal and human studies
(reviewed by Kilbourn et al 25 reported both detrimental and beneficial effects on
blood pressure and survival after (aselective) NOS inhibition in endotoxemia.
However, selective and local inhibition of iNOS in intestinal epithelial cells might
improve intestinal dysfunction in sepsis and endotoxemia and could be a potential
new treatment option.
In conclusion, we have demonstrated a switch from an NF-κB-regulated stress
response to an AP-1-regulated stress response in intestinal inflammation, which is
controlled by the extent of oxidative stress. This switch is probably an adaptation to
the type of stress. NF-kB regulated protective genes include anti-apoptotic genes,
e.g. iNOS, which protect against pro-apoptotic inflammatory cytokines like TNF-α.
AP-1 regulated genes such as HO-1 and superoxide dismutases are more involved in
the protection against various forms of oxidative stress. These findings suggest that
iNOS (NF-κB driven) and HO-1 (AP-1 driven) represent mutual exclusive survival
mechanisms in intestinal epithelial cells.
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ABSTRACT
Background: We have recently shown that the development of colitis in SCID
mice injected with CD45RBhigh CD4+ T cells is dependent on their gut flora. The
mechanisms of this T cell and bacteria dependent induction of colitis are unclear.
Since iNOS is expressed in epithelial cells of the inflamed mucosa of patients with
inflammatory bowel disease (IBD), nitric oxide could be involved in this model of
colitis.
Aim: To study the induction of iNOS in relation to T cell infiltration and cytokine
production in conventionally reared and mono-associated SCID mice in the
CDRB45high CD4+ T cell transfer model of colitis.
Methods: CB-17 SCID mice were reared with conventional flora (CNV) or
mono-associated with H.muridarum, act A (-) mutant L. monocytogenes, Segmented
Filamentous Bacteria (SFB), or O. anthropi under specific pathogen free conditions.
CNV SCID mice were sacrificed 1,2,3,4,5,7,8,13 and mono-associated mice 6 to 11
weeks after injection of the CD45RBhigh CD4+T cells. The iNOS and CD4 proteins
were detected by immunohistochemistry. RT-PCR was performed for iNOS, TNF-α,
IL-1β, IFN-γ, Gro, mMIP mRNA detection.
Results: In CNV SCID mice injected with CD45RBhigh CD4+ T cells an early and
focal, epithelial iNOS expression on the apical site of villi was observed that preceded
the infiltration of CD4+ cells and cytokine production. This epithelial iNOS expression
extended to the entire surface along the whole crypt axis in the course of colitis.
SCID mice monoassociated with H.muridarum developed an severe colitis and showed
high epithelial iNOS expression. CNV- SCID mice without T cells and SCID mice
mono-associated with SFB did not show any iNOS expression, whereas SCID mice
mono-associated with act A(-) mutant L. monocytogenes and O. anthropi showed some
scattered epithelial iNOS staining on the apical site of a few villi, but none of these
mice developed colitis.
Conclusion: Epithelial iNOS expression is an early bacteria dependent event in
the CDRB45high CD4+ T cell transfer model of colitis. These findings suggest that
bacteria specific epithelial cell activation and subsequent iNOS induction and NO
production is important for the development of IBD.
INTRODUCTION
The inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis,
are chronic inflammatory conditions of the gastrointestinal tract. From human and
animal studies it is clear that in IBD an aberrant mucosal T cell response to gut
bacteria plays a major role in the development of the disease. Several animal models
have shown that T helper cells and bacterial flora are needed to induce disease 1.
However, the bacterial species and lymphoid interactions involved are not exactly
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known. In a mono-association study we showed that out of five non-pathogenic
bacteria that in a normal host induce an IgA response, only Helicobacter muridarum
mono-associated severe combined immunodeficient (SCID) mice displayed an
accelerated colitis compared to conventionally reared (CNV) SCID mice after transfer
of CD45RBhigh CD4+ T cells 2. Helicobacter muridarum lives in close contact with
epithelial cells of the crypts 3. Therefore we hypothesized that epithelial cell activation
might trigger the development of colitis in the Helicobacter muridarum associated
mice. In patients with active IBD there is a strong expression of inducible nitric
oxide synthase (iNOS) at the apical side of epithelial cells 4. The induction of iNOS
is mediated by the nuclear factor κB (NF-κB) and it is known that some bacteria can
directly activate NF-κB whereas other bacteria silence the epithelial NF-κB res-
ponse to avoid epithelial cell activation 5. In this study we investigated whether
epithelial iNOS expression and thus NO production is involved in the development
of colitis in CNV reared and mono-associated SCID mice after CD45RBhigh CD4+ T
cell transfer. Therefore we performed a kinetic study in order to relate epithelial
iNOS expression to T cell infiltration and pro-inflammatory cytokine production in
CNV and mono-associated SCID mice We demonstrated an early focal expression
of iNOS in epithelial cells proceeding the T cell infiltration and pro-inflammatory
cytokine production in CNV SCID mice after transfer of naïve T cells. At the termi-
nal stages of colitis both CNV SCID mice as well as Helicobacter muridarum mono-
associated SCID mice showed strong iNOS expression along the whole crypt axis.
In contrast, there was no or very low expression of iNOS in epithelial cells in SCID
mice mono-associated with bacteria that did not induce colitis upon transfer of
naïve T cells. These results demonstrate that bacteria specific epithelial cell activation
and subsequent iNOS induction and NO production is an early event in the
development of colitis in the CD45RBhigh CD4+ T cell transfer model of IBD.
MATERIALS AND METHODS
Animal model
We used the CDRB45high CD4+ T cell transfer model in SCID mice as described 2.
Briefly, C.B-17 SCID mice were reared under conventional (CNV) or mono-associated
conditions. Three weeks after stable colonization of germfree C.B17 SCID mice
(>1010 bacteria/gr feces) with Segmented Filamentous Bacterium, an avirulent actA (-)
mutant DP-L1942 of Listeria monocytogenes or Ochrobactrum anthropi, 5-10x105
CDRB45high CD4+ T cells were injected intraperitoneally into the mono-associated
SCID mice. For the kinetic study of epithelial iNOS expression in conventionally
reared SCID mice 2 mice were sacrificed 1,2,3,4,5,7,8 and 13 weeks after T cell
transfer. Mono-associated mice were sacrificed 6 to11 weeks after T cell transfer.
Normal BALB/c, conventionally and germfree reared SCID mice that did not receive
T cells were used as controls.
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Histology
Specimens of the large intestine were embedded in OCT compound (Miles Inc,
Elkhart, IN) and frozen in 2-methyl-butane with dry ice. Longitudinal sections (4µM)
were fixed with 4% paraformaldehyde, rinsed in PBS, and stained with hematoxylin-
eosin.
Grade of inflammation in tissue sections was evaluated as described2.
Immunohistochemistry
For immunohistochemistry, 7 µm cryostat sections were cut, dried and fixed in
acetone for 10 min at room temperature. For iNOS detection a rabbit polyclonal
antibody developed in our laboratory was used 6. For CD4 detection a monoclonal
biotin conjugated antibody clone H129.19 (Pharmingen,USA) was used. Slides were
incubated with the polyclonal iNOS antibody (1:300) or monoclonal CD4 antibody
(1: 50) in PBS containing 1% BSA for 60 min at room temperature. Subsequently,
endogenous peroxidase activity was blocked by incubating for 30 min in PBS containing
0.075% H2O2. For iNOS detection, peroxidase conjugated goat anti-rabbit Ig (1:50)
and peroxidase conjugated rabbit anti-goat Ig (1:50) all from Dako (Glostrup, Den-
mark) were used as secondary and tertiary antibodies. For CD4 detection
streptavidin-peroxidase (Southern Biotechnology Associates,USA) was used as
secondary step. Color was developed using 3-amino-9-ethylcarbazole (10mg/2.5mL
dimethylformamide in 50 ml 0.05 mol/L acetate buffer pH 4,9) containing 0,03%
H2O2 for 10 minutes at room temperature. Counterstaining was performed with
haematoxylin, and the slides were covered with Kaiser’s glycerin-gelatin.
RNA isolation and reverse-transcriptase polymerase chain reaction (RT-PCR)
RNA was isolated from tissue specimens using Trizol reagent (Sigma Ltd)
according to manufacturer’s instructions. Reverse transcription was performed on
5 µg of total RNA using Oligo-dT primers (Invitrogen) in a final volume of 30 µl.
Polymerase chain reaction (PCR) on cDNA was performed with Taq polymerase
(Invitrogen) on the Biometra PCR system. The PCR primers for mice iNOS, TNF-α,
IL-1β, IFN-γ, Gro, MMIP and β-actin are depicted in table 1. The cycling program was
94°C for 2 min, 58°C for 60 seconds, 72°C for 60 seconds for the first cycle and
Table 1. Primer pairs for RT-PCR
Sense Anti-sense Bp
iNOS 5'-ggtatgctgtgtttggcctt-3' 5'-ggctggacttttcactctgc-3' 390
TNF-α 5'-ctcttcaagggacaaggctg-3' 5'-cggactccgcaaagtctaag-3' 253
IL-1β 5'-caggcaggcagtatcactca-3' 5'-aggccacaggtattttgtcg-3' 350
IFN-γ 5'-actggcaaaaggatggtgac-3' 5'-tgagctcattgaatgcttgg-3' 237
Gro 5'-gctgggattcacctcaagaa-3' 5'-tggggacaccttttagcatc-3' 169
MMIP 5'-agtgaactgcgctgtcaatg-3' 5'-ttcagggtcaaggcaaactt-3' 153
β-actin 5'-cctaaggccaaccgtgaaaag-3' 5'-tcttcatggtgctaggagcca-3' 672
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94°C for 30 sec, 58°C for 60 seconds, 72°C for 60 seconds for 30 cycles. The level
of mRNA expression is expressed relative to the β-actin level.
Statistical Analysis
Significant differences between mean values were determined by Student t test.
RESULTS
Development of colitis
Colitis did not develop in germfree SCID mice and no significant inflammation
occurred in SCID mice mono-associated with SFB, Act A(-) L.monocytogenes or O.
anthropi until 6 to 11 weeks upon T cell transfer (Tabel 2). As shown previously2, H.
muridarum mono-associated SCID mice displayed a more rapid (colitis within 5-6
weeks) and severe inflammation than CNV SCID mice (colitis within 8-11 weeks).
Kinetics of epithelial iNOS induction, T cell infiltration and cytokine production in CNV
reared SCID mice after CD45RBhigh CD4+ T cell transfer
Normal BALB/c and CNV SCID mice did not show any iNOS expression in
their colon tissue. CNV SCID mice showed focal epithelial iNOS already 2 weeks
after T cell transfer (figure 1 left panel). The iNOS expression was on the apical site
of the enterocytes on the top of the crypts and not in the basal crypt epithelial cells.
In week 3 and 4 larger areas of epithelial cells showed iNOS expression but it was
still confined to the top of the crypts. From week 5 also basal crypt epithelial cells
showed iNOS expression. At week 8 the intensity of the iNOS expression had
further increased and involved almost the whole epithelial surface. At the end-stage
of colitis the whole epithelial surface showed a diffuse and intense iNOS expression
along the whole crypt axis. Inflammatory cells showed no iNOS expression. RT-PCR
Table 2.
Intestinal colonization Inflammatory scorea
Conventional 3 ± 0.18b
H.muridarum 4.2 ± 0.27c
SFB 0 ± 0.0d
Act A(-) L.monocytogenes 0.4 ± 0.22d
O.antrhopi 0.2 ± 0.18d
Germ-free 0 ± 0.0
a Tissue section were analyzed according to an inflammation evaluation system 38. Data represent mean ±
SEM.
b Statistical analysis was performed using Student 2-tailed t test. For conventional vs germ-free mice,
P=0.00008
c For conventional vs H.Muridarum mono-associated., P = 0.00005.
d No significant difference was found for SFB, Act A(-) L.monocytogenes, O.anthropi mono-associated vs.
germ-free, respectively (P>0.05).














Figure 1. Immunohistochemistry of the colon for iNOS (left panel) and CD4 (right panel) 1, 2, 3, 4, 5, 7,
8, 13 weeks after transfer of CD45RBhighCD4+T cells into Severe Combined Immunodeficiency mice
(SCID) reared with conventional flora (CNV). The epithelial cells express iNOS 2 weeks after T cell transfer.
In the first weeks this expression is focal and confined to top of the crypts, in the weeks thereafter the
iNOS expression is diffuse and also present in epithelial cells in the basis of the crypts. CD4 positive T
cells are first present  near the muscularis propria (right panel) and expand into the lamina propria after
4 weeks. After 8 weeks the lamina propria is filled with conglomerates of CD4+  T cells.
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Figure 2. RT-PCR for iNOS (mRNA expression relative to expression of β-actin) of the colon  from CNV
reared SCID mice colon 1, 2, 3, 4, 5, 7, 8, 13 weeks after  transfer of CD45RBhighCD4+T cells. The iNOS
mRNA is detectable as early as 3 weeks after T cell transfer.
analysis (figure 2) confirmed the immunohistochemistry results although the RT-
PCR for iNOS was positive shortly after the focal epithelial staining was already
seen at 2 weeks.
Normal BALB/c showed sporadic and CNV SCID had no CD4 positive T cells in
the lamina propria. Upon T cell transfer CNV SCID mice showed small aggregates
of CD4+ T cells near the muscularis propria (figure 1 right panel). After 4 weeks the
cells are no longer present near the muscle but are present in the lamina propria,
sometimes close to epithelial cells. After 8 weeks, expansion and conglomerates of
CD4+ T cells were seen in the lamina propria. At the end-stage of colitis the lamina
propria is filled with conglomerates of CD4+ T cells.
RT-PCR for the pro-inflammatory cytokines IL-1β, TNF-α, IFN-γ and chemotactic
cytokines Gro and mMIP showed equal levels of TNF-α and IFN-γ in BALB/c and
SCID mice that did not receive CD4+ T cells (figure 3). IL-1β and mMIP were reduced
in SCID mice compared to BALB/c mice. The mRNA of the pro-inflammatory
cytokines IL-1β, TNF-α and INF-γ began to rise 3 weeks after T cell transfer and
showed a biphasic response with high peaks around 6 and 10 weeks (figure 3). The
chemotactic cytokine Gro showed the same pattern, whereas another chemokine,
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Figure 3. RT-PCR for mRNA of IL-1β, TNF-α, IFN-γ and the chemokines Gro and mMIP. Equal levels of
TNF-α and IFN-γ mRNA are observed in BALB/c and SCID mice that did not yet receive CD4+ T cells. IL-1β
and mMIP were reduced in SCID mice compared to BALB/c mice. The mRNA levels of the pro-inflammatory
cytokines IL-1β, TNF-α and INF-γ start to increase 3 weeks after T cell transfer and showed a biphasic
response with high peaks around 6 and 10 weeks (figure 3). The chemokine Gro showed the same
pattern, whereas another chemokine mMIP increased only in the terminal phase of colitis
Epithelial iNOS induction in mono-associated SCID mice after CD45RBhigh CD4+ T cell
transfer
Mice mono-associated with SFB did not show any iNOS expression 11 weeks
after T cell transfer (figure 4). Mice mono-associated with Act A(-) L. monocytogenes
and O. anthropi showed very focal iNOS staining 11 weeks after T cell transfer. The
iNOS staining was confined to the apical site of the enterocyte and was only pre-
sent in enterocytes on the top of a few villi (figure 4). However 6 weeks after T cell
transfer mice mono-associated with H. muridarum showed an intense and diffuse
iNOS staining of enterocytes along the whole crypt axis (figure 4).
DISCUSSION
In this study we show that epithelial cells of CNV reared SCID mice express
iNOS early in the development of colitis after CD45RBhigh CD4+ T cell transfer. The
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Figure 4. Immunohistochemistry of the colon for iNOS 11 weeks after transfer of CD45RBhighCD4+T
cells into Severe Combined Immunodeficiency mice (SCID) monoassociated with SFB, L. monocytogenes
Act A (-), O. anthropi or H. muridarum. SFB-monoassociated mice did not induce iNOS expression 11
weeks after T cell transfer. Mice mono-associated with Act A(-) L. monocytogenes and O. anthropi
demonstrated a low level of very focal iNOS staining that was confined to the apical site of the enterocyte
and was only present in enterocytes on the top of a few crypts (arrows). However, mice mono-associated
with H. muridarum showed already 6 weeks after T cell transfer an intense and diffuse iNOS staining of
enterocytes along the whole crypt axis.
absence of epithelial iNOS expression in CNV reared SCID mice that did not receive
naïve T cells demonstrates that both the bacteria and T cells are needed for epithelial
iNOS expression and the development of colitis. The mono-association studies
showed that certain bacteria (e.g. SFB) did not induce iNOS and colitis, whereas
other bacteria (e.g. L. monocytogenes act A(-), O. anthropi) induce a very low level of
iNOS expression, without causing colitis and that some bacteria (e.g. H. muridarum)
give rise to strong epithelial iNOS induction and accelerated colitis.
The induction of iNOS is mediated by the nuclear transcription factor κB (NF-
κB) 7. Because a combination of cytokines (IL-1β, IFN-γ, TNF-α) and endotoxin (LPS)
is needed for the in vitro induction of iNOS in native colon cells and intestinal
SFB L. monocyt. Act A (-)
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tumor cell lines, it is believed that epithelial cells of the colon are relatively resistant
to cytokine induced NF-κB activation. A decreased IκB kinase (IKK) activity and
consequent resistance to IκBα degradation is postulated as a protective response
of intestinal epithelial cells to remain quiescent in the hostile colon environment 8.
However, several enteroinvasive pathogenic organisms such as Salmonella, Shigella,
Listeria and Helicobacter species can directly activate NF-κB 5 and induce iNOS and
pro-inflammatory cytokines in intestinal epithelial cells 9. On the other hand, the
bacterial pathogenic genus Yersinia delivers virulence Yop factors capable of blocking
the NF-κB mediated production of pro-inflammatory cytokines thereby preventing
an anti-bacterial epithelial cell response 10. Apart from pathogenic bacteria there is
also evidence that non-pathogenic bacteria in the normal gut can prevent epithelial
NF-κB induction and thus contribute to reduction of the mucosal immune response
against normal gut bacteria. Therefore, the capability of bacteria to interfere with the
epithelial NF-κB response might reflect its potential to induce or suppress IBD.
Studies aimed at inhibition of NF-κB activation in IBD are promising 11,12. However,
as shown by a conditional epithelial NF-κB knockout animal model an adequate
epithelial NF-κB response is also an important anti-apoptotic response necessary
for epithelial healing and repair 13.
Although we observed a clear correlation between the epithelial iNOS res-
ponse and the development of colitis the exact role of iNOS and epithelial derived
NO in the development of IBD is not known 14. Studies using inhibitors of NOS in
experimental colitis are conflicting and showed little improvement 15,16; no effects 17,18,
or even worse effects 19 on colitis probably due to the lack of iNOS specificity (i.e.
also inhibition of endothelial NOS) of the inhibitors used. In addition, studies of
experimental colitis in iNOS knockout mice also showed conflicting results even
when the same experimental model was used 20-26. IL-10 knockout mice develop
colitis spontaneously. Colitis developed at the same rate and intensity in IL-10
knockout mice and IL-10/iNOS double knockout mice 27. Considering the absence
of macroscopic ulcerations in the presence of large amounts of NO in patients
suffering from microscopic colitis a role of NO in diarrhea and ulcer healing has
been suggested 28. Indeed topical administration of the NOS inhibitor Ng-monomethyl-
L-arginine (L-NMMA) reduced fluid secretion in patients with collagenous colitis 29
and a NO donating mesalazine derivative had an additional beneficial effect on TNBS
induced colitis 30. The reduced gastro-intestinal toxicity of NO-donating non steroidal
anti-inflammatory drugs (NSAID) 31 and aspirin 32 are in agreement with a protective
effect of NO on intestinal epithelial cells. Apart from the above-mentioned beneficial
effects of NO in mucosal injury, NO can also inhibit NF-κB activation 33. Therefore,
high amounts of NO may participate in a negative feedback loop to block prolonged
activation of NF-κB, thereby limiting chronic inflammation.
NO in itself may not be toxic to bacteria, in fact certain enteric bacteria contain
nitrate reductase and produce NO by their own 34. However, as observed in septic
patients, epithelial iNOS induction and NO production may cause increased intestinal
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permeability 35. Indeed selective inhibition of iNOS in endotoxemic rats ameliorated
mucosal permeability for dextran (MW 4000) 36 and reduced bacterial translocation 37.
The absence of bacterial translocation in endotoxemic iNOS knockout mice further
supports a pathogenic role of epithelial derived NO in sepsis. As long as there are
no truly selective iNOS inhibitors available it will be hard to examine the exact role
of epithelial iNOS induction and NO production in IBD. In this study however, we
provide evidence that epithelial iNOS expression is an early and bacteria dependent
event in the development of colitis in the CD45RBhigh CD4+ T cell transfer model of
IBD and that bacteria that cause colitis also induce high epithelial iNOS expression.
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ABSTRACT
The role of nitric oxide (NO) in inflammatory bowel diseases has traditionally
focused on the inducible form of NO synthase (iNOS). However, the constitutive
endothelial (eNOS) and neuronal (nNOS) isoforms may also impact on colitis by
regulating intestinal homeostasis and mucosal integrity. To investigate this, we induced
TNBS colitis in eNOS, nNOS and iNOS-knockout (ko) mice. Both eNOS and iNOS
ko mice developed a more severe colitis compared to wildtype mice. During colitis
iNOS expression dramatically increased on epithelial and lamina propria mononuclear
cells while eNOS remained unchanged and localized to endothelial cells. Electron
and fluorescence microscopy identified bacteria in the ulcerated colonic mucosa of
eNOS ko mice, but not in wildtype, iNOS or nNOS ko mice. Further, eNOS ko mice
had fewer colonic goblet cells, impaired mucin production and exhibited increased
susceptibility to an inflammatory stimulus that was sub-threshold to other mice.
The NO donor isosorbide dinitrate normalized goblet cell numbers and ameliorated
subsequent colitis in eNOS ko mice. These results identify a protective role for both
iNOS and eNOS during colitis, with the loss of eNOS resulting in impaired intestinal
defense against lumenal bacteria and increased susceptibility to colitis.
INTRODUCTION
Several factors have been implicated in the pathogenesis of human Inflammatory
Bowel Diseases (IBD) including an immunological intolerance to enteric microflora 1-4,
as well as defects in mucosal barrier function 5. Recently, attention has focused on
the overproduction of nitric oxide (NO) in IBD 6-7. Several studies have identified
increased levels of NO in the rectal dialysates 8, and in the inflamed mucosa of
patients with UC 9, and in animal models of colitis 10-12. The increased NO synthase
activity was identified predominantly as the inducible form of NO synthase (iNOS) 13.
While the two constitutive isoforms, neuronal (nNOS) and endothelial derived
(eNOS), modulate several aspects of intestinal physiology 14, their contribution to
the inflammatory response has received little attention.
Despite considerable evidence that iNOS-derived NO contributes to tissue
destruction in colitis and other inflammatory states 15, conflicting results have been
obtained using pharmacological inhibitors of NOS in animal models of IBD. Several
studies have found that the nonspecific NOS inhibitor L-NAME reduced intestinal
inflammation 10,16,17, other studies found little benefit 18, or enhancement of colitis 19.
Similar disparate results have been obtained using more selective iNOS inhibitors 20,21.
While these findings may reflect differences in dosing regimens, they may also reflect
the consequences of inhibiting not only iNOS, but also the constitutive forms of
NOS. These limitations have encouraged the study of colitis in mice genetically
deficient in iNOS. Unfortunately, these studies have utilized different protocols and
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yielded conflicting results 22-24. Moreover, the roles of the other NOS isoforms during
gut inflammation have not yet been addressed.
In this study, we have for the first time examined the role of each of the 3 NOS
isoforms in a single model of colitis, using mice genetically deficient in iNOS 25,
nNOS 26 or eNOS 27. Colitis was induced by intra-rectal administration of tri-
nitrobenzene sulfonic acid (TNBS) dissolved in 50% ethanol as a mucosal barrier
breaker. Our results indicate that both iNOS and eNOS knockout (ko) mice develop
an exaggerated and prolonged colitis. The absence of eNOS reduced the integrity of
the colonic mucosa, as reflected by fewer goblet cells and the production of less
mucin. Moreover, only eNOS ko mice developed colitis using TNBS in 30% ethanol
as a barrier breaker, illustrating their increased susceptibility to mucosal injury. Thus
while confirming the protective role of iNOS, these results generate the novel con-
cept that eNOS is critical for colonic mucosal integrity by maintaining goblet cell




Specific pathogen-free, male C57BL/6 mice (6 to 10 weeks old) (Taconic Farms,
Germantown, New York), and 129/J mice (Jackson Laboratories, Bar Harbor, Maine)
were used as wild type mice. iNOS ko mice (on C57BL/6 background) 25 were also
purchased from Jackson Laboratories. The eNOS 27 and nNOS 26 ko mice (mixed
C57BL/6 x 129/J background) were obtained from Massachusetts General Hospital,
Harvard Medical School (H. Mashimo). Experimental protocols followed McMaster
University Animal Care Committee and the Canadian Council on the Use of
Laboratory Animals guidelines.
Colitis Induction and Assessment
Mice were anaesthetized with Enflurane, (Abbott Laboratories, St. Laurent,
Quebec) and given an intra-rectal enema of 6 mg of trinitrobenzene sulfonic acid
(TNBS) (Eastman Kodak Co. Rochester, NY) in 50% EtOH (v/v) (diluted in dH2O)
using a catheter made of PE50 polyethylene tubing attached to a 1ml syringe as
described previously 28. Colonic damage was assessed as previously described 28-29
and a total cumulative score was expressed as the ulcer index (UI).
Myeloperoxidase Activity
Mucosal myeloperoxidase (MPO) activity was measured by colorimetric assay
as described previously 30. In brief, the colonic mucosa was scraped from the underlying
muscularis and weighed. The tissue was homogenized in phosphate buffer (pH 7.4)
containing hexadecyltrimethyl ammonium bromide (HTAB), (Sigma, St. Louis Mo.).
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Homogenates were centrifuged at 15,000 rpm for 20 min and the supernatant was
mixed with o-dianisidine (Sigma) and hydrogen peroxide reagent (Caledon
Laboratories, Georgetown, Ont). The samples were measured at 560 nm, with MPO
activity expressed as units per gram of protein. Protein levels were estimated by the
BCA protein assay (Pierce, Rockford, Illinois).
Measurement of Plasma Nitrite Levels
Plasma nitrite levels were measured by spectrophotometer based on the Griess
reaction. Briefly, blood samples were centrifuged and the supernatant aspirated off.
Blood samples were mixed in 96 well micro titer plates with Griess reagent (1%
sulfanilamide, 0.1% napthyethylenediamine dihydrochloride, 25% H3PO4, Sigma). After
10 min the optical density was measured at 595 nm.
NO Restoration
The NO donor isosorbide dinitrate (Sigma), was administered intra-rectally to
eNOS ko mice in a dose of 20mg/kg every 8h, 3 times per day. After 3 days, colitis
was induced or mice were sacrificed and colonic tissues fixed for histological or
electron microscopical examination.
Histology
Immediately following euthanization, colonic tissues were opened longitudinally,
cleaned and fixed in 10% formalin overnight. Tissues were paraffin embedded, using
standard protocols, sectioned at 3 µm, and stained with haematoxylin and eosin
(H&E) or with periodic acid schiff & haematoxylin (PAS+H) to stain mucus to visualize
goblet cells. For each tissue section goblet cells were counted in areas that included
10 parallel-aligned crypts. Results are expressed as the number of goblet cells containing
PAS stained mucus, per 100 colonocytes.
Immunohistochemistry
Immunostaining for iNOS, eNOS and nitrotyrosine was performed as previously
described 31. In brief, for iNOS detection, a goat polyclonal IgG antibody targeted
against the carboxyl terminus of mouse iNOS (SC 650, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was used. A rabbit polyclonal antibody against the carboxy
terminus of human eNOS (SC 654, Santa Cruz) was used for eNOS detection while
an affinity purified rabbit polyclonal antibody (Upstate Biotechnology, Lake Placid,
NY, USA) was used against nitrotyrosine. Detection was performed using the
streptavidin-biotin-peroxidase complex method using 3-amino-9-ethyl-carbazole as
the chromagen source. Specificity was confirmed as previously described 31.
Fluorescence in situ hybridization
Cryosections (4 µm) were fixed in 4% paraformaldehyde for 24 h at 4°C. Sections
were hybridized overnight in 10 µl of hybridization buffer containing a FITC labeled
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Bact338 probe (reacting with most bacteria) 32, at a concentration of 5ng/ml. Sections
were washed for 20 min at 50°C in hybridization buffer without SDS. Slides were
then dipped in distilled water, dried and mounted using Vectashield (Vector
Laboratories, Burlinghame, Calif). Two people evaluated each section using a
fluorescent microscope. Particles were considered bacteria (seen as a bright green
rods and coccoids against a yellow-brown autofluorescent background) if both
observers agreed.
Electron Microscopy
Colon segments were removed and fixed with 2% glutaraldehyde for 2 h and
post-fixed with 1% osmium tetroxide for 1 h. Tissues were dehydrated through an
alcohol gradient and embedded in EPON. Ultrathin sections were cut at a thickness
of 90 nm and observed with a transmission electron microscope (JEM-1200 EX).
Measurement of colonic mucin glycoprotein release
Colonic mucosal explants (2 x 2mm size) were cultured in 35mm tissue culture
dishes (Becton Dickinson Labware) in 1.5 ml Trowell’s medium containing 10 µCi/ml
of [3H] glucosamine (Du Pont-New England Nuclear) in the presence of antibiotic-
antimycotics (Life Technologies). [3H] glucosamine incorporation into glycoproteins
was determined as previously described 38 and quantified as dpm of 3H glucosamine/g
protein. To confirm [3H] glucosamine was incorporated into mucin, the TCA/PTA
precipitate was examined by density gradient ultra centrifugation as described
previously 33.
Data Presentation and Statistical Analysis
For most experiments, 8-10 mice per group were tested. Results are expressed
as the means ± SEM. Statistical significance was calculated using the Student’s t test
for comparison of two means or a one way analysis of variance (ANOVA) for the
comparison of three or more means. Multiple comparisons were performed using
the Neuman Keuls multiple comparison test. P < 0.05 was considered significant.
RESULTS
Colitis in NOS Isoform Ko Mice
We first examined plasma nitrite levels in NOS isoform ko and wildtype mice
prior to colitis. Circulating nitrite levels were similar in the iNOS ko, nNOS ko and
wildtype mice (4.5 to 4.9 µM) (Table 1), but nitrite levels were significantly lower (P
< 0.01) in eNOS ko mice, at 0.9 ± 0.1 µM, identifying eNOS as the major source of
circulating NO under basal conditions. We next examined the susceptibility of NOS
ko mice to experimental colitis. While colitis did not significantly increase nitrite
levels in iNOS ko mice (5.1 ± 0.7 µM) by day 3, nitrite levels rose significantly in all
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other mouse strains tested (14.6 to 16.0 µM) (see Table 1). Impressive macroscopic
damage was seen by day 3 in the nNOS (UI 7.8 ± 1.1) and the iNOS ko mice (UI 9.1
± 1.0) with ulcer index values similar to wildtype C57BL/6 (UI 8.6 ± 0.8), and 129/J
mice (UI 8.3 ± 1.6) with colitis. However eNOS ko mice exhibited more extensive
and severe colitis, with a significantly higher UI (12.3 ± 1.3) (P < 0.05), compared to
wildtype strains (see Figure 1). Granulocytic infiltration, as assessed by MPO activity,
was also similar in the nNOS ko (17.0 ± 2.9 U/g), C57BL/6 (17.5 ± 2.2 U/g) and 129/J
Table 1. Plasma Nitrite Levels
C57BL/6 129/J nNOS k.o. iNOS k.o. eNOS k.o.
Plasma Nitrite (Basal) 4.7±0.5 4.9±0.7 4.9±0.6 4.5±0.7 0.9±0.1**
Plasma Nitrite (Day 3) 16.0±1.8 15.2±1.6 15.0±5.2 5.1±0.7** 14.6±4.1
Values are concentrations of plasma nitrites in mM, ± 1 SEM for groups of 8-10 mice.
** Significant difference from both C57BL/6 and 129J values under the same conditions (basal or day 3
colitis) (P <0.01).
Figure 1. Histology showing colonic mucosa from a control mouse (A) and on day 3 post TNBS colitis
induction in a C57BL/6 mouse (B), iNOS ko mouse (C) eNOS ko mouse (D). Inflammatory cell recruitment
and tissue pathology were markedly more severe in the eNOS ko mice. (Mag. for all 40x).
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Figure 2. Immunohistochemical detection of iNOS within the colon of normal wildtype C57BL/6 mice
(A), and in C57BL/6 and eNOS and iNOS ko mice during colitis (B to D). Expression of eNOS in uninflamed
C57BL/6 mice (E) and during colitis (F) was also examined. Dark red staining for iNOS was rare in the
colon of normal wildtype mice (A), however expression was evident on epithelial cells (see arrowhead)
and lamina propria mononuclear cells (see arrow) within the same mouse strain during colitis (B). The
number of cells expressing iNOS was greatly increased in tissues taken from eNOS ko mice (C). No iNOS
protein was detectable in tissues taken from iNOS ko mice (D). eNOS expression in the colon of normal
C57BL/6 mice was localized to endothelial cells lining blood vessels (E). During colitis eNOS expression
exhibited a similar localization (by endothelial cells), however the size and number of blood vessels was
greater following colitis (F). (Mag. for A-D 100x, for E-F 40x).
mice (17.0 ± 3.5 U/g). However MPO activity was significantly higher in both the
eNOS (37.5 ± 2.2 U/g) (P < 0.01) and the iNOS ko mice (30.0 ± 6.6 U/g) (p < 0.05).
To examine the influence of NO on healing, we examined NOS ko mice at day
14 post-colitis. While most damage had healed in the nNOS ko (UI 2.7 ± 0.6, MPO
12.0 ±1.1U/g), C57BL/6 (UI 1.8 ± 0.3, MPO 10.0 ± 0.9 U/g), and 129/J mice (UI 1.6 ±
0.4, MPO 9.6 ± 2.2 U/g), tissue injury and inflammation were still evident in the
eNOS (UI 3.4 ± 0.7, MPO 18.0 ± 2.0 U/g) and iNOS ko mice (UI 3.5 ± 0.5, MPO 20.0
± 2.1 U/g) with all inflammatory markers significantly higher than in wildtype mice
(P < 0.05). Thus eNOS and iNOS isoforms not only protect against an initial colitis
injury but also contribute to mucosal healing.
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Immunostaining for iNOS and eNOS
Little iNOS expression was seen in the colons of wild type mice without colitis
(Figure 2A) but strong iNOS expression was seen on colonocytes and lamina prop-
ria mononuclear cells during colitis (Figure 2B). iNOS staining in the nNOS ko mice
was seen only during colitis and was similar to that seen in wildtype mice (not
shown). In contrast, moderate staining for iNOS protein was seen in epithelial and
mononuclear cells in eNOS kos, even in the absence of colitis, but staining was
limited to sites adjacent to lymphoid follicles (not shown). As shown in Figure 2C,
iNOS staining increased in the eNOS ko mice during colitis. As expected, iNOS ko
mice did not express immunoreactive iNOS protein under any condition (Figure
2D).
In wildtype mice, eNOS expression was limited to endothelial cells lining colonic
blood vessels (Figure 2E), and did not change following induction of colitis. However
the size and number of blood vessels, particularly within the lamina propria, increased
during colitis (Figure 2F). eNOS expression was localized to the endothelial cells of
colonic blood vessels in all strains tested. The size and number of eNOS staining
blood vessels increased during colitis.
Figure 3. Immunohistochemistry for nitrotyrosine within the colon of normal wildtype mice (A), and in
wildtype and eNOS and iNOS ko mice during colitis (B to D). Dark staining for nitrotyrosine was rare in
the colon of control C57BL/6 wildtype mice (A), however expression was evident on lamina propria
mononuclear cells of wildtype mice during colitis (B). Note that epithelial cells did not express nitrotyrosine.
Nitrotyrosine expression in both eNOS ko (C) and iNOS ko mice (D) was found in a similar pattern to that
in colitic wildtype mice, but the frequency of positively staining cells was greater. (Mag. for A & B 20x,
for C & D 40x).
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Immunostaining for Nitrotyrosine
One cytotoxic mechanism of NO is through its interaction with superoxide to
produce peroxynitrite that causes the nitration of amino acid residues such as tyrosine.
Thus while NO has a short half-life, nitrotyrosine epitopes are stable and tend to
accumulate in inflammatory cells. Nitrotyrosine positive cells were rare in the uninflamed
colon from all mouse strains (see Figure 3A). During colitis, nitrotyrosine staining
was found predominantly in lamina propria mononuclear cells and more of these
cells stained positively for nitrotyrosine than for iNOS. Interestingly, no nitrotyrosine
staining was seen on epithelial cells during colitis (Figure 3B), however studies in
culture show NO is released apically from epithelial cells and is unlikely to form
peroxynitrite. Endothelial cells were also negative for nitrotyrosine. While all mouse
strains showed increased levels of nitrotyrosine staining during colitis, the iNOS ko
(Figure 3C) and the eNOS ko (Figure 3D) mice showed the greatest staining. The
former finding implies that both iNOS dependent and independent pathways are
active during TNBS colitis, leading to the formation of nitrotyrosine 34,35.
Bacterial Translocation
In view of the role colonic microflora play in the TNBS colitis model 36, we
examined colonic tissues for bacteria using electron microscopy and fluorescence in
situ hybridization (FISH), using commercial probes that recognize the 16S RNA of
most commensal enteric bacteria 32. While bacteria were occasionally identified
within the adherent mucus layer overlying the colonic epithelium, no bacteria were
seen within the mucosa of control mice (Figure 4A).
Figure 4. Fluorescence in situ hybridization for bacteria within colonic tissues from uninflamed (A) or
colitic mice (B & C). No bacteria were identified within the lamina propria of C57BL/6 mice either prior
to (A) or during colitis (not shown), nor in colitic iNOS ko mice (B). However numerous bacteria (yellow-
green – see arrow) were found within the mucosa of colitic eNOS ko mice (C) and electron microscopy
confirmed the presence of numerous bacteria within the mucosa of colitic eNOS ko mice (D). (Mag. for
A-C 100x, for D 5000x).
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Despite the mucosal ulceration induced by TNBS, no bacterial penetration of
the mucosal barrier was seen in wildtype, nNOS or iNOS ko mice (Figure 4B). In
contrast, large numbers of bacteria were identified just beneath ulcerated areas in
the eNOS ko mice. As seen in Figure 4C, fluorescing bacteria appeared to be
translocating across the colonic mucosa. The presence of bacteria within the colonic
mucosa of colitic eNOS ko mice was confirmed by electron microscopy (see Figure
4D). No bacteria were seen in the tissues of wildtype, nNOS or iNOS ko mice (not
shown).
Susceptibility to Colitis
To determine whether eNOS and iNOS ko mice suffered from an inability to
down-regulate the inflammatory response, or from an increased susceptibility to
the initial insult, we administered TNBS in only 30% ethanol. (rather than the nor-
mal 50%). As shown in Table 2, little damage was seen in wildtype, nNOS or iNOS ko
mice. In contrast, eNOS ko mice developed significant ulceration (P < 0.05) and
MPO activity (P < 0.05). Thus the exaggerated colitis seen in eNOS ko mice reflects
an increased susceptibility to the initial insult.
Table 2. Colitis in response to 30% ethanol
C57BL/6 129/J nNOS k.o. iNOS k.o. eNOS k.o.
Ulcer Index 1.4±0.1 1.2±0.2 0.8±0.4 1.1±0.3  4.0±0.3*
Myeloperoxidase 10.2±1.2 9.7±1.5 8.1±1.1 7.6±1.5 20.0±2.0*
Values are in arbitrary units for ulcer index and in units of activity per gram of protein for myeloperoxidase
± 1 SEM for groups of 8-10 mice.
* Significant difference from both C57BL/6 and 129J values (P <0.05).
Goblet Cell Numbers and Function
In pursuit of this increased susceptibility to colitis, histological analysis identified
a significant reduction in the number of superficial PAS-positive goblet cells per 100
colonocytes in eNOS ko mice (5.4 ± 1.0) compared to control C57BL/6 mice (14.2
± 1.7, P < 0.001) (Figure 5). In contrast, nNOS ko and iNOS ko mice had numbers of
goblet cells (12.8 ± 1.7 and 15.2 ± 1.8 respectively) similar to wildtype numbers.
Electron microscopy revealed that goblet cells in eNOS ko mice were smaller and
contained less mucus than in wildtype mice (see Figure 5). Moreover, mucin release
from eNOS ko colonic explants was significantly decreased compared to control
C57BL/6 mice (4.1 ± 0.8 dpm of 3H glucosamine/g protein vs 11.5 ± 1.4 dpm, P<
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Figure 5. Histology showing PAS staining of goblet cells (purple) (Panels A-C) and electron micrographs
of goblet cells (Panels D-F) from the colonic mucosa of a control C57BL/6 mouse (A & D) an eNOS ko
mouse (B & E) and an eNOS ko mouse treated with the NO donor isosorbide (C & F). Note the reduced
number of PAS positive goblet cells found in the eNOS ko mice (B), compared to those in wildtype mice
(A). eNOS ko goblet cells appear smaller and contain less mucus (E) than those in wildtype mice (D).
Following isosorbide treatment, goblet cell numbers (C) and mucus content (F) normalized in the treated
eNOS ko mice. (Mag. for A-C 400x, for D-F 5000x).
0.001) as well as iNOS and nNOS ko mice (10.4 ± 1.6 dpm/g and 12.0 ± 1.6 dpm/g
respectively). As studies in colitic eNOS ko mice found that goblet cell numbers
significantly increased by day 3 post TNBS (18.1 ± 1.7, P < 0.001), we reasoned that
the eNOS ko goblet cell deficiency reflected a potentially reversible response to
reduced NO production, rather than a developmental deficiency in goblet cell
formation.
NO Donor Normalizes Goblet Cell Number and Ameliorates Colitis
We attempted to reconstitute normal colonic function in eNOS ko mice by
intra-rectal administration of the NO donor isosorbide nitrate. Treatment normalized
goblet cell number (17.4±1.6) and mucus content and structural integrity (Figure 5)
in eNOS ko mice. As shown in Figure 6, the subsequent induction of colitis in these
NO-reconstituted mice was significantly ameliorated (UI 9.0±0.7, MPO 29.9±2.6)
compared to untreated eNOS kos with colitis (UI 12.3±1.3, MPO 37.5±2.2, P<
0.05).
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DISCUSSION
iNOS is believed to represent the major source of NO in IBD 12. Histological
studies have identified intense focal iNOS expression by the inflamed bowel epithelium
and in the mononuclear cell infiltrate from the gut of both CD and UC patients 31,37.
We therefore reasoned that iNOS would play a pivotal role in experimental intestinal
inflammation. Indeed our data suggest that NO produced by iNOS is the major
source of the increased plasma nitrite seen during experimental colitis. iNOS
expression strongly increased during TNBS colitis and as in UC patient tissues 31,
was expressed predominantly by epithelial cells at sites proximal to inflammatory
infiltrates, as well as by lamina propria mononuclear cells. Like McCafferty et al., 22,23
we found that iNOS ko mice exhibited a more severe and protracted colitis. The
absence of iNOS expression under control conditions suggests that iNOS plays its
beneficial role after the induction of colitis. Indeed we found no evidence that iNOS
deficiency altered the susceptibility of the colon to an inflammatory insult or to
microbial translocation. The counter-inflammatory effects of iNOS-derived NO are
poorly understood but may involve the maintenance of mucosal perfusion, the prevention
of mast cell activation, and a reduction in leukocyte adherence to endothelium 38.
The co-localization of nitrotyrosine with iNOS expression was observed in
monocytes in keeping with recent studies in tissues from IBD patients 31 and in rats
with TNBS-induced colitis 39. Like previous studies 31, we did not see nitrotyrosine
staining in epithelial cells. Since iNOS expression by cultured enterocytes is
accompanied by apical NO release 40, this was not unexpected. However, as epithelial
cells are not professional phagocytes, the function of iNOS in epithelial cells is not
clear. An anti-microbial role against lumenal bacteria is suggested by studies in which
enteroinvasive bacteria induce iNOS expression by cultured epithelial cells 41, similar
to the effects of several pro-inflammatory cytokines 40.
Figure 6. Histology showing colonic pathology on day 3 post-colitis induction in eNOS ko mice without
(A) or with isosorbide pretreatment (B). Note that the inflammatory cell recruitment, edema and tissue
pathology were reduced in the isosorbide treated eNOS ko colitic mouse. (Mag. 20x for all).
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Our study indicates that nNOS does not play a significant role in the generation
of the inflammatory response induced by TNBS in the mouse, unlike in some asthma
models where its actions are crucial 42. Studies in experimental colitis have shown
that the inflammatory process disrupts NADPH diaphorase staining in gut tissues 18,
while nNOS expression by enteric nerves is altered in UC patient tissues 43. These
observations suggest colitis affects both NO based neurotransmission and
gastrointestinal motility 44.
Our results suggest that eNOS is the major contributor to circulating nitrite
levels under normal conditions Both prior to and during colitis, eNOS expression
was restricted to colonic vascular endothelium, as has been found in IBD 31. In the
absence of eNOS, basal plasma nitrite levels were reduced. However, during colitis,
nitrite levels in eNOS ko mice increased to levels similar to those seen in wildtype
colitic mice, likely reflecting NO of iNOS origin. Indeed, iNOS expression was readily
detected in tissues from colitic eNOS ko mice, indicating that eNOS deficiency did
not interfere with iNOS expression.
Our study indicates that eNOS plays a major role in protection against TNBS-
induced colitis and bacterial translocation. In this model, 50% ethanol acts as a mucosal
barrier breaker, facilitating the entry of the haptenizing agent TNBS into the colonic
mucosa, where it modifies host proteins. Unlike the other mouse strains tested,
eNOS ko mice developed significant colitis in response to TNBS dissolved in 30%
ethanol, demonstrating a weakened mucosal barrier that we attribute to a striking
deficit in goblet cell numbers and mucin production. Several studies have implicated
goblet cells and mucus production as important factors protecting the colon against
injury 45-47, while others have identified abnormalities in mucin production in IBD 48,49.
Unfortunately it is unclear if these changes are causal or are secondary to the disease
process. Our study indicates that the eNOS dependent goblet cell deficiency was a
contributing factor to the exaggerated colitic response seen in the eNOS ko mice.
Following the normalization of goblet cell numbers by locally administering a NO
donor to the colon, subsequent colitis was significantly attenuated. While a direct
effect of NO on goblet cells is possible, eNOS has been traditionally thought to act
as a vasodilator. Therefore, eNOS deficiency may impair blood flow to the mucosa,
resulting in poor growth and function of goblet cells.
The identification of significant numbers of microorganisms near ulcerated areas
of the colon in only eNOS ko mice leads us to also conclude that eNOS-derived
NO plays an important role in defense against bacterial translocation. This may
reflect the actions of eNOS derived NO in mediating the vascular relaxation seen
during inflammation 50 such that the loss of eNOS may prevent the mucosal immune
system from effectively dealing with the translocated bacteria. Given the importance
of enteric microflora and epithelial barrier function in IBD, it is tempting to speculate
that eNOS derived NO may play an important role in the pathogenesis of IBD.
Indirect support for this comes from a recent study showing that early onset of UC
in a Japanese population was associated with polymorphisms of the eNOS gene 51.
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Unlike other genetic deletions that result in spontaneous colitis if the animals are
kept under conventional, but not germfree housing, none of the NOS ko strains
showed any signs of spontaneous intestinal inflammation in this study. We therefore
propose that under homeostatic conditions, the mucosal barrier of the eNOS ko
mice provides adequate protection against lumenal products, with exaggerated
inflammation and bacterial translocation seen only when this mucosal barrier is
challenged. Such a genetically predisposed susceptibility to lumenal challenge may
have implications not only for IBD but also for determining a host’s susceptibility to
enteric pathogens.
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Chapter 8
Blockade of NF-κB Activation and Donation
of Nitric Oxide: New Treatment Options
in Inflammatory Bowel Disease?
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ABSTRACT
Background: Inhibition of NF-κB activation has been suggested as an anti-
inflammatory treatment strategy in inflammatory bowel disease (IBD). However,
NF-κB regulated genes like inducible nitric oxide synthase (iNOS) are also involved
in cell survival mechanisms.
Methods: Review of the literature on NF-κB activation and iNOS induction in
IBD.
Results: In patients with IBD the mucosal immune response is derailed. The
nuclear transcription factor NF-κB is a key regulator of the inducible expression of
many genes involved in immune and inflammatory responses in the gut. Various
stimuli like oxidative stress, cytokines (IL-1, IL-6, TNF-α), bacteria and viruses can
release NF-κB from its inactive cytoplasmatic form to the nucleus. Drugs like
corticosteroids, sulfasalazine, mesalazine and inhibitory cytokines (eg IL-10, IL-11)
can prevent the activation of NF-κB. New, more potent and selective treatment
strategies with anti-sense p65, proteasome inhibitors and viral IκBα expression
vectors aim at the prevention of NF-κB activation in mucosal macrophages and T
lymphocytes. However NF-κB regulated genes are also involved in survival respon-
ses of epithelial cells. For example inhibition of the NF-κB mediated induction of
iNOS in epithelial cells could block important anti-apoptotic and anti-microbial
survival mechanisms. Nitric Oxide (NO) may also serve in a negative feedback loop
to antagonize prolonged activation of NF-κB, thereby limiting chronic inflammation.
Conclusion: Luminal donation of nitric oxide could block NF-κB activation.
Selective inhibition of NF-κB activation in inflammatory cells could be a treatment
option in inflammatory bowel disease.
INTRODUCTION
Despite non-specific barriers like lysozyme, acid and mucus there is a constant
interaction between the content of the gut lumen, epithelial cells and the mucosal
immune system. The mucosal immune system continuously checks the lumenal con-
tent for potential pathogenic microorganisms. The presence of inflammatory cells in
small and large bowel biopsies from healthy subjects reflects this normal mucosal
immune response. Induction of tolerance will prevent activation of the mucosal
immune system against the normal gut content. In case of infection there is a quick
response of the innate immune system followed by an adaptive immune response
that will lead to resistance towards repeated infection. After antigen recognition
and immune activation the adaptive immune response will decline leaving a specific
memory behind. In chronic inflammatory bowel disease (IBD) there is a derailed
mucosal immune response leading to chronic non-specific inflammation of the gut
wall. The activation of mucosal macrophages and T cells plays a central role in the
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pathogenesis of IBD 1. The nuclear transcription factor NF-κB is a key regulator of
the inducible expression of many genes involved in immune and inflammatory res-
ponse in the gut 2;3. Many of the current drugs for treatment of IBD prevent NF-κB
activation but are not very specific. Several new treatment strategies are aimed at
the selective blockade of NF-κB activation in mucosal macrophages and T cells.
However NF-κB also regulates genes that protect cells against apoptotic cell death
from the evoked inflammatory response. Nitric Oxide (NO) derived from inducible
nitric oxide synthase (iNOS) and other inhibitors of apoptosis (e.g. cIAP1 & 2) are
NF-κB regulated genes involved in cell survival. Therefore, in case of selective bloc-
kade of NF-κB activation in T cells, epithelial cells should be protected against the
blockade of NF-κB mediated survival pathways. In this review we address the potential
of NF-κB blockade by NO donation as new treatment options in IBD.
NF-κB activation in the inflammatory response
The nuclear factor κB was originally described as a heterodimeric complex of
two subunits (p65 and p50) able to bind a specific DNA sequence in the enhancer of
the immunoglobulin κ light gene 4. It is now known that NF-κB includes a family of
proteins (RelA=p65, RelB, C-Rel, p50, p52) which in the cytoplasm are bound to
inhibitors of κB (IκB-α, IκB-β, p105, p100, IκB-γ, IκB-ε, Bcl-3) 5. Upon stimulation,
IκB proteins are phosphorylated by IκB kinases (IKKs), polyubiquitinated and degraded
by the 26 S proteasome. Various stimuli like viruses, microbial products,
proinflammatory cytokines (TNF-α, IL-1, IL-6), T-and B-cell mitogens, physical and
chemical stress can release NF-κB proteins from the inactive cytoplasmatic com-
plex 2. Once released, dimers of the NF-κB family translocate to the nucleus and
bind to dimer specific consensus DNA sequences leading to activation of transcription
of cytokines, growth factors, adhesion molecules, cell surface receptors, acute phase
proteins and other transcription factors. Many NF-κB regulated genes are upregulated
in the inflamed mucosa of patients with IBD 6. An increased amount of NF-κB p65
was found in nuclear extracts from colonic biopsy samples in Crohn’s disease patients 7.
Electrophoretic mobility shift assays (EMSA) of nuclear extracts from lamina prop-
ria mononuclear cells showed increased NF-κB binding in both Crohn’s disease and
ulcerative colitis patients 7. Rogler et al 8 used a monoclonal antibody that detects
only the released subunit p65 of NF-κB. With this antibody activated NF-κB was
detected in macrophages and epithelial cells of the inflamed mucosa. It is known
that the anti-inflammatory properties of aspirin and salicylate are mediated in part
by their specific inhibition of IKK-β, thereby preventing NF-κB activation 9. Important
drugs in IBD therapy like mesalazine and glucocorticosteroids can also block the
NF-κB signalling pathway. Mesalazine prevents the IL-1 induced phosphorylation of
p65 10 and sulfsalazine can inhibit both IκB kinases α and β 11. Glucocorticoids keep
NF-κB in its inactive cytoplasmatic form by increasing the IκB mRNA and protein
expression 12;13. The anti-inflammatory cytokines IL-10 14 and IL-11 15 also inhibit NF-
κB activation. More selective inhibition of NF-κB activation has been proposed as a
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treatment option in IBD 3;6. Indeed systemic and local administration of anti-sense
p65 improved TNBS colitis in mice, colitis in IL-10 knockout mice and decreased the
production of IL-1, IL-6 and TNF-α in lamina propria macrophages from patients
with Crohn’s disease 16. Other approaches using proteasome inhibitors 17;18 and
adenoviral delivery of dominant negative IκB proteins 19;20 caused blockade of NF-
κB activation in vitro. Further development of selective NF-κB inhibitors may lead
to novel anti-inflammatory drugs as effective as glucocorticoids but without the
steroid side-effects .
NF-κB activation in the survival response
In addition to the NF-κB mediated regulation of the host immune and inflamma-
tory response, NF-κB family members are also involved in cell growth and differentiation,
cell survival, and adaptive responses to changes in cellular redox balance 21. For
example, mice lacking the p65 subunit (RelA) die during embryonic development,
because of extensive apoptosis of liver cells 22. Aberrant regulation and chronic
stimulation of NF-κB activation has been associated with the pathogenesis of several
diseases including cancer 23. The intestinal barrier in the gut is composed of a rapidly
replaced monolayer of intestinal epithelial cells (IEC). As a defense against the potential
pathogenic gut content, IEC’s develop unique protective responses. In order to prevent
activation by the normal gut flora a relative resistance to NF-κB activation has been
suggested 24. Pathogenic organisms like Salmonella, Shigella, Listeria and Helicobacter
species can activate NF-κB in IEC 25. Other bacteria like Yerisina Enterocolitica contain
virulence factors capable to induce IEC apoptosis and inhibit NF-κB mediated TNF-α
secretion in macrophages 26. Apart from protection against bacterial invasion, IEC’s
can also protect themselves against oxidative stress generated by inflammatory cells
present in inflammatory bowel disease. Reactive oxygen intermediates like superoxide
radicals (O2•-), hydrogen peroxide (H2O2) and hydroxyl radicals (OH•) can activate
NF-κB 21.This will lead to the induction of superoxide dismutase (SOD) a potent
anti-oxidative enzym 27. Since NF-κB is affected by oxidative stress, proteins like
thiodredoxin (TRX) keep NF-κB in the reduced state 28. Thus, NF-κB can act as a
redox sensor of the cell. In case of severe oxidative stress NF-κB is oxidized and
cannot activate anti-apoptotic survival pathways anymore 29. NF-κB activation leads
to resistance towards TNF-α induced apoptosis 30. On the one hand resistance to
apoptosis could lead to uncontrolled cell growth 31 on the other hand it is necessary
for the restoration of the epithelial cells barrier function 32.
Nitric Oxide: a component of the NF-κB mediated survival response?
Inducible nitric oxide synthase is a NF-κB mediated enzyme capable of producing
large amounts (micromolar) of NO for a longer period of time. Although iNOS ex-
pression has been documented in inflammatory 33;34 and endothelial cells 35, epithelial
cells 33;34;36;37 seem to be the main cell type expressing iNOS in the inflamed gut of
patients with IBD. Because a combination of cytokines (IL-1, IFN-γ, TNF-α) and
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endotoxin (LPS) are needed for the in vitro induction of iNOS in native colon cells
and in intestinal tumour cellines these cells are believed to be relatively resistant to
cytokine induced NF-κB activation 24. A decreased IKK activity and consequently
resistance to IκBα degradation is postulated as a protective response of IEC’s to
remain quiescent in the hostile colon environment 2. However enteroinvasive bacteria
like E. coli, Salmonella dublin or Shigella flexneri can directly induce iNOS expres-
sion 38 suggesting an important role of iNOS in the intestinal anti-bacterial res-
ponse. Early studies focused on the pathogenic role of NO in IBD. NO can react
with superoxide (O2•-) anions yielding the toxic reactive nitrogen intermediate
peroxynitrite (OONO-) 39. In addition to its role as an oxidizing agent, peroxynitrite
can nitrosylate tyrosine yielding 3-nitrotyrosine residues in proteins. Evidence for
peroxynitrite mediated damage of epithelial cells in IBD was found in one 33 but not
in two other studies 34;36. Studies using inhibitors of NOS in experimental colitis,
showed little improvement 40;41; no improvement 42;43, or even aggravated 44 colitis.
The first report of experimental colitis in iNOS knockout mice showed delayed
healing and persistent inflammation in acetic-acid induced colitis 45. Studies with
trinitrobenzene sulphonic acid (TNBS) induced colitis in iNOS knockout mice showed
resistance to colitis in one 46, and increased inflammation in two other studies 47;48.
Also the dextran sulfate sodium (DSS) model of colitis in iNOS knockout mice
showed resistance to DSS in one 49 and aggravation of colitis in another study 50.
Furthermore, a chronic colitis which develops spontaneously in interleukin 10 (IL-10)
deficient mice, developed at the same rate and intensity in mice which were deficient
in both IL-10 and iNOS genes 47. Considering the absence of macroscopic ulcerations
in the presence of large amounts of NO in patients with microscopic colitis a
protective role of NO is suggested 51. Indeed, NO donating mesalazine had a beneficial
effect on TNBS induced colitis over and above that of mesalazine alone 52. The reduced
gastro-intestinal toxicity of NO donating non steroidal anti-inflammatory drugs
(NSAID) 53 and aspirin 54 are in agreement with a protective role of NO on intestinal
epithelial cells. The suggested mechanisms for the protective role of NO in colitis
include a direct antimicrobial effect 55, the scavenging of superoxide radicals, the
inhibition of leukocyte and platelet adhesion, maintainance of mucosal perfusion
and inhibition of apoptosis and NF-κB activation. The inhibitory effect of NO on
apoptosis and NF-κB activation may occur as a result of nitrosylation of redox sensitive
sites in the apoptotic effector enzyme caspase-3 56 and in the NF-κB signalling
pathways 57;58 respectively (Figure 1). Therefore high amounts of NO may serve in a
negative feedback loop to block prolonged activation of NF-κB thereby limiting
chronic inflammation.
C H A P T E R  8
106
CONCLUSION
In inflammatory bowel disease NF-κB is activated in mucosal macrophages, T
cells and epithelial cells of the inflamed mucosa. Genes regulated by NF-κB are
involved in both inflammatory and survival responses. Commonly used drugs in IBD
like mesalazine, sulfasalazine and glucocorticoids inhibit NF-κB activation. New
selective inhibitors like antisense p65, dominant negative IκBα proteins and proteasome
inhibitors are directed at components of the signal induction pathway of NF-κB. The
role of NO produced by iNOS in IBD is not clear, this to a large extent is due to the
lack of a true selective iNOS inhibitor. Nitric oxide produced by iNOS may act in a
negative feedback loop on NF-κB activation (Figure 1). Since NF-κB is also involved
in controlling cell growth and apoptosis one must be cautious with long term
inhibition of its activity. However transient NF-κB inhibition could offer novel
treatment options in IBD.
Figure 1. Effects of drugs and Nitric Oxide (NO) on NF-κB activation and apoptosis pathways.
(1) Sulfasalazine can inhibit both IκB kinase α & β. (2) Glucocorticoids increase IκB mRNA and protein
expression. (3) Mesalazine prevents phosphorylation of the NF-κB p65 subunit. (4) Anti-sense p65
inhibit p65 mRNA and protein expression. (5) Proteasome inhibitors prevents IκB degradation. (6) IκB
expression vectors deliver IκB protein. (7) Nitric Oxide can act in a negative feedback loop by oxidation
of NF-κB (NF-κB-SX) thereby preventing NF-κB binding to DNA and by inhibition of IκB phosphorylation.(8)
Nitric oxide also inhibits the apoptosis pathway by inhibiting caspase-3 activity. RIP: receptor interacting
protein, TRAF-2: TNF receptor associated factor, TRADD: TNF receptor 1-associated death domain,
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SUMMARY
Intestinal inflammation is almost invariably accompanied by intestinal dysfunction
which constitutes a major clinical complication. Current therapy is often inadequate
due to incomplete knowledge about the mechanisms causing intestinal dysfunction
in intestinal inflammation. Nitric oxide (NO) may be a key component in this process.
This thesis is focused on the expression, regulation and function of the enzyme
inducible nitric oxide synthase (iNOS) in intestinal inflammation. In chapter 1 the
function of the three NOS isozymes nNOS, eNOS and iNOS in the gastrointestinal
tract are discussed. Small (nanomolar) amounts of Nitric Oxide (NO), produced by
calcium-dependent nNOS, have a physiological role in peristalsis and sphincter
function of the intestine. Decreased nNOS function can result in a-peristalsis and
obstructive sphincters. NO produced by eNOS dilates mucosal blood vessels and
prevents leucocyte aggregation and is thereby essential for the maintenance of
mucosal blood flow. Absence of eNOS derived NO results in an increased suscepti-
bility of the gastrointestinal tract to injury. Selective NO delivery by gene therapy or
by NO donating compounds might offer new therapeutic options in motility dis-
orders of the gut and the prevention of mucosal injury. The effects of large (micromolar)
amounts of NO as produced by iNOS are less well understood. Large amounts of
NO can increase gut permeability, induce apoptosis and stimulate intestinal secretion
while NO can also kill bacteria, block apoptosis and reduce inflammation by inhibiting
NF-κB activation. Therefore, inhibition of nitric oxide generation could have both
beneficial and deleterious effects. In chapter 2 we identified intestinal epithelial
cells as the main cellular source of inducible nitric oxide synthase (iNOS) in mucosal
biopsies from patients with active inflammatory bowel disease (IBD). Since NO can
react with superoxide anions (O2•-) yielding the toxic oxidizing agent peroxynitrite
(ONOO-) we also studied peroxynitrite induced nitration of tyrosine residues
(nitrotyrosine) in proteins. Superoxide anion producing cells were present in increased
numbers in the lamina propria of IBD patients. Nitrotyrosine formation was not
observed in epithelial cells but only in superoxide-anion producing inflammatory
neutrophils and mononuclear cells. These findings indicate that tissue damage in
IBD is probably more related to reactive oxygen species (ROS) producing inflammatory
cells than to NO producing epithelial cells. In this study a low level of iNOS expression
was also observed in tissue macrophages. Since tissue macrophages are derived
from circulating monocytes, we studied iNOS expression in circulating monocytes
and related this expression to disease activity and to markers of monocyte activation.
This study is described in chapter 3. The expression of iNOS in circulating monocytes
was increased in patients with active IBD compared to healthy controls. The patients
who went into remission all had marked reduction of iNOS expression in circulating
monocytes. Surface markers for monocyte activation CD63 and CD11b, were not
elevated and HLA-DR expression was decreased in circulating monocytes from
patients with active ulcerative colitis. This may suggest a suppressive function of NO
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on systemic monocyte activation. In chapter 4 we used a model of endotoxemia
and an intestinal epithelial cell line (DLD-1) to study the epithelial iNOS and heme-
oxygenase-1 (HO-1) expression in response to inflammation and oxidative stress.
Endotoxin, or lipopolysaccharide (LPS) injected in rats, induced iNOS, but not HO-1
in intestinal epithelial cells of the ileum and colon. The thiol-modifying agent
diethylmaleate (DEM) strongly induced HO-1 both in epithelial cells and lamina
propria inflammatory cells. Combined treatment with LPS and DEM decreased iNOS
expression, but strongly induced HO-1 expression. Similarly, cytokine mix (CM)
induced iNOS expression, but not HO-1 expression in cultured intestinal epithelial
DLD-1 cells. DEM and the lipid peroxidation end product 4-HNE prevented iNOS
induction in a NF-κB dependent manner, but increased the HO-1 expression in CM-
exposed DLD-1 cells. Thus, we demonstrate an opposite regulation of iNOS and
HO-1 in intestinal epithelial cells in response to cytokine exposure and DEM or 4-
HNE-induced oxidative stress. These findings suggest that iNOS (NF-κB driven) and
HO-1 (AP-1 driven) represent complementary survival mechanisms in intestinal
epithelial cells. In chapter 5, we studied the kinetics of iNOS expression in relation
to T cell infiltration and cytokine production in conventional-reared (CNV) and
with one bacteria-associated severe combined immunodeficient (SCID) mice in the
CDRB45high CD4+ T cell transfer model of colitis. In CNV-SCID mice injected with
CD45RBhigh CD4+ T-cells an early and focal, epithelial iNOS expression on the apical
site of crypts was observed that preceded the infiltration of CD4+ cells and cytokine
production. This epithelial iNOS expression extended to the entire epithelial surface
along the entire crypt axis in the course of colitis. SCID mice monoassociated with
the bacteria H.muridarum developed an accelerated colitis and showed high epithelial
iNOS expression. CNV-SCID mice without T-cells and SCID mice mono-associated
with Segmented Filamentous Bacteria did not show any iNOS expression, SCID mice
mono-associated with act A(-) mutant L. monocytogenes and O. anthropi showed some
scattered epithelial iNOS staining on the apical site of a few crypts, but none of
these mice developed colitis. These findings suggest that T-cells and bacteria-dep-
endent epithelial iNOS expression is an early event in the CDRB45high CD4+ T-cell
transfer model of colitis. In order to determine whether epithelial iNOS induction
is detrimental or beneficial and to establish the role of the two constitutive isoforms
of NOS we investigated the development of TNBS-induced colitis in mice genetically
deficient for inducible nitric oxide synthase (iNOS), constitutive endothelial (eNOS)
and neuronal (nNOS) isoforms in chapter 6. Both eNOS and iNOS deficient mice
showed a more severe colitis than wildtype and nNOS deficient mice. In wildtype
mice eNOS localization in endothelial cells was unchanged by colitis, however, iNOS
expression was dramatically increased in epithelial cells and lamina propria
mononuclear cells. Fluorescent and electron microscopy identified bacteria
translocating across the inflamed lamina propria of eNOS deficient mice, but not in
wildtype, iNOS or nNOS deficient mice during colitis. The increased susceptibility
of eNOS deficient mice was associated with a decrease in colonic goblet cell numbers
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and impaired mucin production. Intra-rectal delivery of the NO donor isosorbide
dinitrate normalized mucin production and ameliorated subsequent colitis. These
results suggest a protective role of both iNOS and eNOS during experimental colitis.
The absence of eNOS caused an impaired intestinal defense against lumenal bacteria
and a concomitant aggravation of colonic inflammation. Finally, in chapter 7, we
discuss whether blockade of NF-κB activation and donation of nitric oxide could be
new treatment options for inflammatory bowel disease. The transcription factor
NF-κB is a key regulator of the expression of genes involved in immune and
inflammatory responses in the gut. Various stimuli like oxidative stress, cytokines
(IL-1, IL-6, TNF-α), bacteria and viruses can release NF-κB from its inactive
cytoplasmatic form to the nucleus. Drugs like corticosteroids, sulfasalazine, mesalazine
and inhibitory cytokines (eg IL-10, IL-11) can prevent the activation of NF-κB. New,
more potent and selective treatment strategies with anti-sense NF-κB-subunit p65,
proteasome inhibitors which prevent degradation of Iκ-B protein and viral IκBα
expression vectors aim at the prevention of NF-κB activation in mucosal macrophages
and T lymphocytes. However NF-κB regulated genes are also involved in survival
responses of epithelial cells. For example inhibition of the NF-κB mediated induction
of iNOS in epithelial cells could block important anti-apoptotic and anti-microbial
survival mechanisms. Nitric Oxide (NO) may also serve in a negative feedback loop
to antagonize prolonged activation of NF-κB, thereby limiting chronic inflammation.
Therefore lumenal donation of nitric oxide could block NF-κB activation. Selective
inhibition of NF-κB activation in inflammatory cells and donation of NO could be a
treatment option in inflammatory bowel disease. Further studies with intestinal
NO donation or very selective iNOS inhibitors are needed before this can be applied
in clinical practice.
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Nederlandse Samenvatting voor niet-ingewijden
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NEDERLANDSE SAMENVATTING VOOR NIET-INGEWIJDEN
De ziekte van Crohn en colitis ulcerosa zijn chronische ontstekingsziekten van
de darm. Ondanks het feit dat de precieze oorzaak van de darmontsteking nog niet
is opgehelderd, is er de laatste jaren wel grote vooruitgang geboekt in het onderzoek
naar het ontstaan en de behandeling van deze aandoeningen. Deze chronische
ontstekingsziekten van de darm (Inflammatory Bowel Disease = IBD) ontstaan in
genetisch gevoelige personen als gevolg van een ontspoorde afweerreactie tegen in
de darm aanwezige stoffen, afkomstig van bacteriën die normaal in de darm
voorkomen. Toenemend inzicht in de verschillende onderdelen van deze afwijkende
afweerreactie in de darmwand heeft geleid tot nieuwe medicijnen en een beter
begrip van werkingsmechanismen van bekende medicijnen. In dit proefschrift werd
onderzocht of het gas stikstofmonoxide (NO) een rol zou kunnen spelen bij
ontsteking van de darm. Stikstofmonoxide is chemisch een radicaal (sterk reactieve
stof) dat, vooral geproduceerd wordt door stikstofmonoxidesynthase (Nitric Oxide
Synthase = NOS). Twee vormen van deze NOS enzymen produceren voortdurend
kleine hoeveelheden NO die een belangrijke rol spelen bij de zenuwfunctie (neuronaal
NOS = nNOS) of het openhouden van bloedvaatjes (endotheliaal NOS = eNOS).
Dit proefschrift richt zich vooral op het NOS enzym dat onder normale omstandigheden
niet in de darm aanwezig is maar wel tot expressie kan worden gebracht (induceerbaar
NOS = iNOS) en dan voor een beperkte tijd grotere hoeveelheden NO kan pro-
duceren. Een grote hoeveelheid NO zou een rol kunnen spelen bij darmontsteking
zoals die voorkomt bij patiënten met IBD of bij een gestoorde darmfunktie zoals dat
voorkomt bij patiënten met een bloedvergiftiging (sepsis). Aangezien de meeste
radicalen zeer agressieve stoffen zijn die met andere moleculen reageren en dan
weefsels kunnen beschadigen onderzochten we de aanwezigheid van iNOS bij IBD
en bij sepsis. Mocht dit enzym inderdaad aanwezig zijn dan zou het remmen van dit
enzym een nieuwe behandeling kunnen zijn voor patiënten met deze ziekten. In het
hoofdstuk 1 wordt een overzicht gegeven van de rol die NO speelt in het normaal
functioneren van het maagdarmkanaal. Kleine hoeveelheden door nNOS geproduceerd
NO spelen een rol bij de darmperistaltiek en het openen van sluitspieren. Bij
afwezigheid van nNOS kan de darm niet normaal meer bewegen en blijven de
sluitspieren gesloten. NO geproduceerd door eNOS in de bloedvaatwand zorgt
ervoor dat er voldoende bloed naar de darm kan gaan. Remming of afwezigheid van
het eNOS maakt de darm kwetsbaarder voor zuurstoftekort of beschadiging. Bij
ziekten met een gestoorde darmperistaltiek of problemen met sluitspieren wordt
getracht via gentherapie nNOS verhoogd tot expressie te brengen. Om het schadelijke
effect van sommige medicijnen op het maagdarmslijmvlies te voorkomen wordt aan
deze medicijnen soms een stof toegevoegd die NO afgeeft. Het is nog niet goed
bekend wat het effect is van het geven van grotere hoeveelheden NO zoals bijvoorbeeld
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door het enzym iNOS wordt gemaakt. Enerzijds zouden grotere hoeveelheden NO
kunnen lijden tot darmverlamming, diarree of het kapot maken van de darmbarrière.
Anderzijds zou de inductie van iNOS een verdediging kunnen zijn tegen bacteriën.
Het remmen van de aanmaak van NO kan dus zowel gunstige als ongunstige effecten
hebben. In het hoofdstuk 2 beschrijven we het onderzoek waarbij we slijmvlies van
de darm van patiënten met een actieve ziekte van Crohn of colitis ulcerosa hebben
onderzocht op de aanwezigheid van het enzym iNOS. Het iNOS enzym bleek
voornamelijk in cellen die de binnenbekleding van de darm vormen (darmepitheel-
cellen) voor te komen. Om te onderzoeken of het aldaar geproduceerde NO ook
schadelijke effecten had, hebben we gekeken naar de aanwezigheid van indirect door
NO veroorzaakte schade van de darmepitheelcellen. Vreemd genoeg vonden wij
alleen door NO beschadigde eiwitten op het oppervlak van ontstekingscellen maar
niet op het oppervlak van epitheelcellen. Het was voor ons dan ook aannemelijker dat
ontstekingscellen mogelijk een belangrijker rol speelden bij het veroorzaken van
darmbeschadiging dan het door darmepitheel geproduceerde NO. Bij het zoeken
naar de aanwezigheid van het iNOS eiwit in de darmbiopten vonden wij ook een
geringe aanwezigheid van iNOS in ontstekingscellen die normaal gesproken eiwitten
aan het afweersysteem kunnen presenteren (weefsel macrophagen). Aangezien
weefselmacrophagen voortkomen uit in bloed circulerende monocyten onderzochten
we in hoofdstuk 3 de aanwezigheid van iNOS in bloedmonocyten. We ontdekten
inderdaad dat het iNOS eiwit, zij het in geringe mate, aanwezig was in monocyten
afkomstig uit bloed van patiënten met een actieve darmontsteking. De aanwezigheid
van iNOS in deze monocyten daalde zodra de darmontsteking genezen was. Vreemd
genoeg waren er geen aanwijzingen dat deze circulerende monocyten geactiveerd
waren (geen verhoogde aanwezigheid van de eiwitten CD63 and CD11b) , sterker
nog: een herkenningsmolecuul (HLA-DR) dat nodig is om stoffen aan het afweersysteem
te presenteren bleek juist minder in de iNOS bevattende monocyten voor te komen.
Dit suggereerde dat het in de monocyten geproduceerde NO mogelijk een rol zou
kunnen spelen bij het onderdrukken van de activatie van circulerende monocyten.
Omdat er tijdens ontsteking altijd veel door zuurstofradicalen ontstane schade
ontstaat (oxidatieve stress), onderzochten wij in hoofdstuk 4 de inductie van iNOS
en heme oxygenase-1 (HO-1), in aan of afwezigheid van oxidatieve stress. HO-1 is
een belangrijk verdediging enzym tegen oxidatieve stress. Daarnaast produceert
HO-1 koolmonoxide (CO) hetgeen ontstekingsremmend kan werken. Het effect
van oxidatieve stress op de expressie van iNOS en HO-1 onderzochten we in een
model voor bloedvergiftiging (sepsis) in ratten en in gekweekte menselijke dikke darm-
epitheelcellen. Wanneer we een belangrijk bacterieël product (lipopolysaccharide =
LPS) bij de rat inspoten werd iNOS wel, maar HO-1 niet, geïnduceerd in darm-
epitheelcellen van de dunne- en dikke darm. Wanneer we door zuurstof radicalen
veroorzaakte stress nabootsen door het inspuiten van diethylmaleate (DEM) werd
HO-1 wel, maar iNOS weer niet, geïnduceerd in zowel epitheel- als ontstekingscellen.
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Wanneer we zowel bloedvergiftiging nabootsen door toediening van LPS en
tegelijkertijd de ratten behandelden met DEM werd er veel minder iNOS maar veel
meer HO-1 gemaakt door de darmepitheelcellen. Ook in gekweekte darm-
epitheelcellen kon met een mengsel van ontstekingseiwitten, wel iNOS maar geen
HO-1 geïnduceerd worden. Na toediening van DEM of 4-hydroxynonenal, (dat
vrijkomt wanneer de wanden van epitheelcellen beschadigd raken) aan de gekweekte
epitheelcellen werd er wel HO-1 maar geen iNOS geïnduceerd. Wanneer de
gekweekte epitheelcellen met zowel het mengsel van ontstekingseiwitten als DEM
of 4-HNE werden behandeld, werd iNOS niet meer, en het HO-1 in sterkere mate
geïnduceerd. De remming van de iNOS inductie door DEM en 4-HNE bleek
veroorzaakt te worden doordat deze stoffen een signaalmolecuul (nuclear factor
κB) blokkeren, dat nodig is de celkern aan te zetten tot activatie van het iNOS gen
dat er voor zorgt dat het iNOS eiwit gemaakt wordt. Wij vonden dus een
tegengestelde regulatie van iNOS en HO-1 in darmepitheelcellen. Bij schade
veroorzaakt door zuurstofradicalen, werd het iNOS eiwit niet meer aangemaakt in
darmepitheelcellen, terwijl HO-1 eiwit juist in sterk verhoogde mate wordt
aangemaakt. Dit betekent dat er bij veel door zuurstofradicalen veroorzaakte schade
niet langer NO maar wel CO wordt aangemaakt. In hoofdstuk 5 werd de inductie
van iNOS in een experimenteel model van IBD bestudeerd. Hierbij werden muizen
gebruikt die van zichzelf geen afweercellen van het B en T cel type hebben
(zogenaamde Severe Combined Immuno Deficient = SCID muizen). Wanneer deze
muizen ingespoten werden met niet getrainde helper T cellen (deze hebben het
eiwit CD4 en weinig eiwit CD45 op hun oppervlak), ontwikkelen ze een
darmontsteking wanneer ze opgroeien met hun normale darmbacteriën. Het bleek
dat het iNOS eiwit al heel vroeg in de ontwikkeling van de darmontsteking in de
epitheelcellen van de dikke darm aanwezig was. Wanneer de muizen geen T helper
cellen kregen ingespoten of zonder bacteriën waren opgegroeid, kregen ze geen
darmontsteking en was er geen inductie van het iNOS eiwit. We ontdekten dus dat
je zowel bacteriën als T helper cellen nodig hebt om iNOS in darmepitheelcellen te
kunnen induceren en om een darmontsteking te kunnen krijgen. Natuurlijk zouden
we graag willen weten welke bacteriën wel en welke bacteriën niet iNOS inductie
en een darmontsteking zouden kunnen veroorzaken. Om die reden lieten we SCID
muizen opgroeien met vier afzonderlijke soorten bacteriën waarvan we wisten dat
deze bacteriën wel een afweerreactie maar geen darmziekte veroorzaakten in normale
muizen. Het bleek dat SCID muizen die alleen opgegroeid waren met de bacterie H.
muridarum veel sneller en een ernstiger darmontsteking lieten zien na injectie met
de T helper cellen dan muizen die waren opgegroeid met 3 andere bacteriestammen.
Dit geeft aan dat je zowel bepaalde type bacteriën als T helper cellen nodig om
iNOS in epitheelcellen te induceren en IBD te ontwikkelen. Alhoewel het ontstaan
van een darmontsteking dus vaak samengaat met de inductie van het iNOS eiwit
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wisten we niet zeker of deze inductie nu goed of slecht was voor de ontwikkeling
van IBD. Om die reden onderzochten we in hoofdstuk 6 het ontstaan van IBD na
toediening van een allergische stof (TNBS) in de dikke darm van muizen die door
genetische manipulatie het gen voor het iNOS, eNOS of nNOS eiwit misten. Muizen
die geen eNOS en iNOS eiwit konden maken lieten een ergere darmontsteking zien
dan de muizen die dit wel konden. Het bleek dat de darmwand van de muizen
zonder eNOS veel meer bacteriën doorlieten dan de normale muizen of de muizen
zonder iNOS of nNOS. Tevens bleek dat de slijmvormende cellen van het darmepitheel
veel minder slijm konden maken in de muizen die het eNOS eiwit niet konden
maken. Wanneer deze muizen stikstofmonoxide via een medicijn kregen toegediend
maakten ze veel beter slijm en hadden de muizen een minder ernstige darmontsteking.
Het lijkt er dus op dat het stikstofmonoxide afkomstig van eNOS en iNOS een
beschermend effect heeft op een darmontsteking. In hoofdstuk 7, tenslotte bespreken
we het remmen van het signaalmolecuul NF-κB en het toedienen van NO als nieuwe
behandelingsmogelijkheden bij IBD. Afgezien van de inductie van iNOS is het NF-κB
ook een belangrijk signaalmolecuul voor inductie van veel genen die een rol spelen
bij een darmontsteking zoals die aanwezig is bij IBD. Verschillende stimuli zoals
zuurstofradicalen, ontstekingseiwitten (IL-1, IL-6, TNF-α), bacteriën en virussen zijn
in staat NF-κB te activeren. Medicijnen zoals prednison, sulfasalazine en mesalazine
maar ook ontstekingsremmende eiwitten (IL-10, IL-11) remmen NF-κB activatie.
Nieuwe behandelingsstrategieën zijn gericht op het specifiek remmen van het NF-
κB. Hierbij wordt gebruik gemaakt worden van DNA (anti-sense p65) of RNA (RNAi)
gericht tegen de aanmaak van NF-κB, medicijnen die de afbraak van de remmer van
NF-κB remmen (proteasoom remmers) of virale IκBα expressie vectoren, die de
aanmaak van de remmer stimuleren. Deze selectieve NF-κB remming moet dan
gericht zijn tegen NF-κB activatie in weefsel macrophagen en T helper cellen en niet
tegen NF-κB activatie in darmepitheelcellen aangezien NF-κB gereguleerde genen
betrokken zijn bij verdedigings-, en overlevingsresponsen van deze darmepitheelcellen.
De inductie van iNOS is mogelijk één van deze verdedigings-, en overlevingsresponsen
van darmepitheelcellen. Alvorens echter het geven van NO te overwegen als nieuwe
behandelingmethode van IBD dient er eerst verder onderzoek te worden verricht
met medicijnen die NO alleen in de darm afgeven of medicijnen die alleen iNOS en
niet nNOS of eNOS remmen.
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DANKWOORD
Arts zijn is een prachtig beroep zeker wanneer je de patiëntenzorg kunt combi-
neren met onderwijs en onderzoek. Het is toch geweldig om een nog onbeant-
woorde vraag voortgekomen uit de zorg voor patiënten (from bed), via laborato-
rium onderzoek (to bench) te beantwoorden zodat je dit weer ten goede kunt laten
komen van de patiënt (and back). Dit soort translationeel onderzoek spreekt mij
enorm aan en zodra je de hedendaagse mogelijkheden van “de bench” hebt leren
kennen gaat er een hele wereld voor je open. Onderzoek doen is bij mij onlosmake-
lijk verbonden geweest met mijn opleiding tot eerst internist en later maag-darm-
leverarts. Onderzoek doen moet je, net als patiëntenzorg, leren. Dit proefschrift is
een weergave van die leerfase waarbij zowel basale onderzoekers als clinici hebben
bijgedragen tot mijn wetenschappelijke vorming. Zonder volledig te kunnen zijn wil
ik in dit dankwoord de mensen bedanken die hiertoe hebben bijgedragen.
Om te beginnen wil ik mijn vrouw Alice Holwerda bedanken dat ze mij vanaf
mijn eerste studiejaar heeft bijgestaan en mij ook nu heeft gesteund in mijn keuze
voor een academische carrière zelfs, toen hier een maandenlang verblijf, zonder
gezin, in Amerika aan vast zat. Alice, jij kent me als geen ander en weet wat voor
impact dit soort werk op mij, jou, ons gezin en ons leven heeft. Gelukkig weet jij
altijd inspanningen op verschillende terreinen van het leven goed te verdelen. Mede
door jou hoef ik nu niet in het dankwoord te schrijven dat ik na mijn promotie meer
tijd met Jan-Dirk, Tjerk-Jippe, Jurjen en Anna-Maaike zal doorbrengen. De promotie
is dan misschien wat later dan aanvankelijk gedacht (gelukkig nog wel net voor mijn
veertigste) maar ik had het niet sneller willen doen ten koste van jou en ons gezin.
Dit proefschrift gaat over stikstofmonoxide bij darmontsteking en mijn co-pro-
motor Han Moshage was degene die het stikstofmonoxide-onderzoek naar ons lab
heeft gebracht. Beste Han, alhoewel van oorsprong een hepatologisch georiënteerde
onderzoeker heb je altijd oog gehad voor darmziekten. Jou onderzoek naar eerst
fibrose, later oxidatieve stress en nu apoptose zijn onderwerpen waar de clinici zich
prima bij aan kunnen sluiten. We hebben veelvuldig gediscussieerd over het verband
tussen kliniek (“de witte jassen”) en het laboratorium en ik denk dat wij met jou en
Klaas-Nico Faber uitstekend verder kunnen bouwen aan een goed translationeel
laboratorium voor de maag-,darm- en leverziekten.
 Peter Jansen, mijn promotor, heeft samen met Han Moshage en Michael Müller
het MDL-laboratorium opgebouwd. Beste Peter, jij bent met je scherpe verstand
mijn voorbeeld geweest hoe modern wetenschappelijk onderzoek uitgevoerd moet
worden. Je hebt me geleerd te waken voor “fenomenologie” en je was ons met je
ideeën vaak ver vooruit. Het is jammer dat je in Groningen niet altijd begrepen werd
en dat je voor nieuwe uitdagingen terug bent gegaan naar het Academisch Medisch
Centrum in Amsterdam. Je hebt in ieder geval een klinkend laboratorium en een
goede opleiding achtergelaten waarvoor dank.
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De hulp van een pathologisch georiënteerd onderzoeker is voor veel onder-
zoek noodzakelijk. Met name in de begintijd van het onderzoek heeft mijn co-pro-
motor Harry van Goor als pathologie researcher mij veel geholpen. Beste Harry,
alhoewel jij je vooral bezighoudt met nieronderzoek draai je ook voor darmonderzoek
je hand niet om. Je hebt mij en Alie de Jager-Krikken met praktische raad en daad
bijgestaan waarvoor dank. Nier en darm hebben beide epitheel dus we zullen ons in
de toekomst wellicht wel vaker op dat vlak vinden.
Voor iemand die kliniek en onderzoek combineert is een analist onontbeerlijk
en ik ben de firma’s AstraZeneca B.V. en ALTANA Pharma B.V. dan ook erkentelijk
voor de jarenlange financiële ondersteuning van analisten in ons laboratorium. Drie
analisten (Alie de Jager-Krikken, Manon Buist-Homan en Lisette Bok) hebben mij bij
mijn onderzoek geholpen en als ik drie paranimfen mocht hebben zou ik ze alle drie
op die manier graag voor het voetlicht willen halen.
 Beste Alie , jij was de eerste analist met wie ik werkte en je hebt me als geen
ander kennis leren maken met immuunhistochemische technieken. Inmiddels weet
ik dat een kleuring niet alleen van laboratorium tot laboratorium maar ook van
persoon tot persoon zeer kan verschillen. Af en toe mis ik nog je gouden handjes.
Na een avontuur buiten het AZG werk je inmiddels weer in Groningen; ik wens jou
en je gezin veel geluk toe.
Beste Manon, na je goed uitgevoerde stage ben je aanvankelijk voor Han en mij
gaan werken. Inmiddels ben je een “senior technician” geworden die niet alleen
immuunhistochemische maar ook de modernste moleculair-biologische laborato-
rium technieken beheerst. Je labjournaal is zo goed dat ook experimenten van jaren
terug goed terug te vinden zijn. Jou werkwijze mag als voorbeeld gelden voor an-
dere analisten.
Beste Lisette, ook jij kon nadat de sponsoring rond was na je stage, speciaal
voor mij op ons lab blijven werken. Ik heb inmiddels ervaren wat een luxe dit voor
een dokter is. Samen hebben we in Omaha, Nebraska, USA ons bezig gehouden met
dunne darm transplantatie. Een heel nieuwe onderzoeksgebied in een nieuwe om-
geving; het ging je allemaal gemakkelijk af. Je hebt zo langzamerhand zoveel
laboratoriumervaring opgedaan dat we je eigenlijk ook maar “senior technician”
moeten gaan noemen.
De leden van de beoordelingscommissie (Prof.dr.S.Poppema, Prof.dr.T.H.The en
Prof.dr.J.H.Kleibeuker) wil ik bedanken voor de vlotte beoordeling van het manu-
script. Ik ben blij dat een belangrijke GUMC-bouwer als Prof.dr.S. Poppema kennis
heeft willen nemen van dit soort “ translationeel” werk, volgens mij vormt dergelijk
onderzoek het hart van een goed functionerend universitair medisch centrum.
Prof.dr.T.H.The is een van de professoren die het belang van dokters die basaal
onderzoek doen onderkent en ook heeft uitgewerkt in de oprichting van de Junior
Scientific Masterclass. Hij was het, die mij voor het eerst bij Jurjen Schirm kennis
heeft laten maken met onderzoek doen. Zijn woorden, bij zijn afscheidscollege ge-
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sproken, over de voldoening die de waarheidsvinding in de klinische wetenschap kan
geven, klinken mij nog steeds als muziek in de oren. Prof.dr.J.H. Kleibeuker, beste Jan,
zoals Peter mij vooral wetenschappelijk vormde was jij nadrukkelijk betrokken bij
mijn gastroenterologie opleiding. Zowel bij het leren van endoscopie, als supervisor
van de polikliniek (de korte briefjes op de gedicteerde brieven) en kliniek, jij legde
overal een degelijke basis. Ik weet zeker dat je als nieuw hoofd van de afdeling maag-
,darm- en leverziekten ons tot een goed team zult gaan smeden.
Een proefschrift kun je van tevoren niet geheel plannen en het gaat soms onver-
wachte richtingen op, waarbij je extra hulp nodig hebt. Werken met monocyten was
zo’n richting waarbij ik hulp nodig had. Anneke Muller Kobold en Geert Mesander
hebben mij geleerd monocyten te “FASCen”. Peter Heeringa en André Zandvoort
(ja André jij hebt dus ruim gewonnen) konden gelukkig bijspringen met de monocyten
isolatie en stimulatie. Jan-Willem Cohen Tervaert en Arjan van de Loosdrecht we-
zen me op de vele pittfalls met monocyten. De hulp van Richard List bij vele compu-
ter- en automatiseringsproblemen wil in hier niet onvermeld laten. Ook in het wer-
ken met diermodellen voor IBD heb ik samengewerkt met groepen die ervaring
hadden met deze modellen.
Dear Bosheng Qiu, Bruce Vallance and other members of Steven Collins group,
we were the first groups suggesting a beneficial role for iNOS in IBD. I was happy to
collaborate with you on the experimental colitis model in NOS knock out mice and
hope our paper will be published soon.
Nico Bos wil ik bedanken dat we dankzij zijn contacten met de groep van John
Cebra de relatie tussen iNOS inductie in epitheelcellen, bacteriën, en T cellen aan
konden tonen. Ik zie er naar uit om in de toekomst samen dit soort onderzoek in
Groningen verder uit te bouwen.
 Een speciaal woord van dank gaat uit naar onze AGIKO Hans Blokzijl. Ik herken
zoveel in jou enthousiasme voor onderzoek en kliniek. Ik ben blij dat ik je een beetje
mag begeleiden en ben je dankbaar voor je hulp bij het labwerk en bij het verkrijgen
van biopten; het ga je goed.
Onderzoek en patiëntenzorg zijn bij mij altijd verweven geweest. Ik wil dan ook
van de gelegenheid gebruik maken om alle medewerkers van de MDL-afdeling (o.a.
Gonny en Petra), verpleegafdeling D3VA, het Endoscopiecentrum, het Dagcentrum,
de Polikliniek (o.a. Bert, Agnes, Karin en Tilly) bedanken voor hun plezierige samen-
werking. Hierbij gaat een speciaal dankwoord uit naar Prof.dr. Rutger Ploeg en Hendrik
van Dullemen.
 Beste Rutger en Hendrik, jullie waren het die mij hebben gevraagd niet naar de
periferie te vertrekken maar in het AZG te blijven om samen met jullie te werken
aan dunnedarmtransplantatie en Inflammatory Bowel Disease. Ik deel jullie visie dat
dit inderdaad een ideale combinatie is met veel mogelijkheden voor de toekomst.
Laten we hopen dat we in het toekomstige GUMC onze plannen ten aanzien van
IBD en dunnedarmtransplantatie verder uit kunnen bouwen.
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Ik heb het voorrecht momenteel met een aantal van mijn vroegere opleiders
samen te werken in de staf. Bram Limburg, Frans Peters, Els Haagsma, Aad van den
Berg en de inmiddels vertrokken Rob de Knegt (Rotterdam), Ids Klompmaker (As-
sen) en Leo Meerman (Leeuwarden). Van ieder van jullie heb ik specifieke dingen
geleerd.Je opleiders (en dat waren er met een volledige interne en MDL opleiding
vele) blijven langdurig in je herinnering en gelukkig zijn deze herinneringen plezierig
waarvoor dank.
Van mijn collega assistenten uit de Groninger MDL school Hugo Wolters, Janneke
van der Woude, Laurens van der Waaij (gelukkig dichtbij in het Martini ziekenhuis
werkzaam, zodat we samen kunnen blijven werken) en Liekele Oostenbrug ben ik
de enige die is blijven hangen; ik denk dat jullie het met me eens zijn dat we samen
een leuke opleidingstijd hebben gehad. De Groningse gastronomische traditie moe-
ten we als oud gastroenterologie-assistenten wat mij betreft ook na het vertrek van
Peter in ere houden.
Tenslotte wil ik alle patiënten bedanken die bloed of biopten voor dit onder-
zoek hebben afgestaan. We weten nog niet precies hoe de ziekte van Crohn of
colitis ulcerosa ontstaat en hoe we deze ziekte het beste kunnen behandelen. Het
iNOS-enzym is een interressant eiwit om te bestuderen maar helaas kan ik nog niet
definitief zeggen of u er iets aan zou hebben als we dit enzym zouden remmen. We
komen echter steeds verder in het begrijpen van deze darmziekten. Dit proefschrift
is mijn eerste bijdrage hieraan en u kunt van mij verwachten dat ik hier verder mee
ga.
Gerard Dijkstra
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woorden
vaak zijn het maar wat tekens
in een bepaald verband
pasmunt voor sociale verveling
maar soms geven ze geluid








(gedicht van mijn leraar Nederlands, Dick Ellen)
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